90 results on '"Hamstra D"'
Search Results
2. Hippocampal Sparing Radiotherapy in adults with Primary Brain Tumors: A comparative planning and dosimetric study using IMPT, IMRT and 3DCRT
- Author
-
Aka, P, Taylor, R, Hugtenburg, R, Lambert, J, Powell, J, Bevolo, T, Gao, M, Gondi, V, Hartsell, W.H, Bolsi, A, Beer, J, Belosi, M.F, Siewert, D, Lomax, A.J, Weber, D.C, Huang, Y.J, Huang, C.C, Chao, P.J, Liu, C, Shang, H, Ding, X, Wang, Y, Mammar, H, Froelich, Sébastien, Alapetite, Claire, Bolle, Stéphanie, Calugaru, Valentin, Feuvret, Loic, Helfre, Sylvie, Champion, Laurence, Goudjil, Farid, Dendal, Remi, Engelholm, S.A, Munck Af Rosenschold, P, Kristensen, I, Smulders, B, Muhic, A, Alkner, S, Jacob, E, Engelholm, S, Aljabab, S, Lui, A, Wong, T, Liao, J, Laramore, G, Parvathaneni, U, Kharouta, M, Pidikiti, R, Jesseph, F, Smith, M, Dobbins, D, Mattson, D, Choi, S, Mansur, D, Machtay, M, Bhatt, A, Lütgendorf-Caucig, C, Dunavölgyi, R, Georg, P, Perpar, A, Fussl, C, Konstantinovic, R, Ulrike, M, Piero, F, Eugen, H, Vidal, M, Gerard, A, Barnel, C, Maneval, D, Herault, J, Claren, A, Doyen, J, Dendale, R, Toutee, A, Pasquie, I, Goudjil, F, Lumbroso Lerouic, L, Levy, C, Desjardins, L, Cassoux, N, Elisei, G, Pella, A, Calvi, G, Ricotti, R, Tagaste, B, Valvo, F, Ciocca, M, Via, R, Mastella, E, Baroni, G, Saotome, N, Yonai, S, Makishima, H, Hara, Y, Inaniwa, T, Sakama, M, Kanematsu, N, Tsuji, H, Furukawa, T, Shirai, T, Sauerwein, W, Finger, P.T, Gallie, B, Gavrylyuk, Y, Thariat, J, Salleron, J, Maschi, C, Fevrier, E, Caujolle, J.P, Hofverberg, P, Angellier, G, Peyrichon, M.L, Breneman, J, Esslinger, H, Pater, L, Vatner, R, Habrand, J.L, Stefan, D, Lesueur, P, Kao, W, Véla, A, Geffrelot, J, Tessonnier, T, Balosso, J, Mahé, M.A, Lim, P.S, Rompokos, V, Chang, Y.C, Royle, G, Gaze, M, Gains, J, Vennarini, S, Francesco, F, Rombi, B, Amichetti, M, Schwarz, M, Lorentini, S, Mee, T, Burnet, N.G, Crellin, A, Kirkby, N.F, Smith, E, Kirkby, K.J, Roggio, M, Buwenge, M, Melchionda, F, Ammendolia, I, Ronchi, L, Cammelli, S, Morganti, A.G, Youn, S.H, Kim, J.Y, Park, H.J, Shin, S.H, Lee, S.H, Hong, E.K, Czerska, K, Winczura, P, Wejs-Maternik, J, Blukis, A, Antonowicz-Szydlowska, M, Rucinski, A, Olko, P, Badzio, A, Kopec, R, Franceschini, D, Cozzi, L, De Rose, F, Meattini, I, Fogliata, A, Cozzi, S, Becherini, C, Tomatis, S, Livi, L, Scorsetti, M, Garda, A, Fattahi, S, Michel, A, Mutter, R, Yan, E, Park, S, Corbin, K, Giap, H, LAM, W.W, Geng, H, Tang, K.K, Lee, T.Y, Kong, C.W, Yang, B, Chiu, T.L, Cheung, K.Y, Yu, S.K, Ma, M, Gao, X, Zhao, Z, Zhao, B, Mullikin, T, Routman, D, Yu, J, Greco, K, Fagundes, M, Shan, J, Daniels, T, Rule, W, DeWees, T, Hu, Y, Bues, M, Sio, T, Liu, W, chenbin, L, yuehu, P, yuenan, W, Bai, Y, Gao, X.S, Zhao, Z.L, Ma, M.W, Ren, X.Y, Salem, A, Woolf, D, Aznar, M, Azadeh, A, Eccles, C, Charlwood, F, Faivre-Finn, C, Teoh, S, Fiorini, F, George, B, Vallis, K, Van den Heuvel, F, Huang, E.Y, Juang, P.J, Pan, S, Hawkins, M, Clarke, M, Lowe, M, Radhakrishna, G, Schaub, S, Bowen, S, Nyflot, M, Chapman, T, Apisarnthanarax, S, Vitek, P, Kubes, J, Vondracek, V, Vinakurau, S, Zamecnik, L, Vitolo, V, Barcellini, A, Brugnatelli, S, Cobianchi, L, Vanoli, A, Fossati, P, Facoetti, A, Dionigi, P, Orecchia, R, Iannalfi, A, Vischioni, B, Ronchi, S, D’Ippolito, E, Petrucci, R, Yamaguchi, H, Honda, M, Hamada, K, Todate, Y, Seto, I, Suzuki, M, Wada, H, Murakami, M, Yu, Z, Zheng, W, Lien-Chun, L, Zhengshan, H, Qing, Z, Jiade, L, Guoliang, J, Fiore, M.R, D'Ippolito, E, Fukumitsu, N, Hayakawa, T, Yamashita, T, Mima, M, Demizu, Y, Suzuki, T, Soejima, T, Hartsell, W, Collins, S, Casablanca, V, Mihalcik, S, Brennan, E, Van Nispen, A, Corbett, A, Mohammed, N, Lee, P, van Nispen, A, Liang, Y.S, Mein, S, Kopp, B, Choi, K, Haberer, T, Debus, J, Abdollahi, A, Mairani, A, Ogino, H, Iwata, H, Hashimoto, S, Nakajima, K, Hattori, Y, Nomura, K, Shibamoto, Y, Li, P, Wu, S, Deng, L, Zhang, G, Zhang, Q, Fu, S, Yang, Z, Zhang, Y, Sasaki, R, Okimoto, T, Akasaka, H, Miyawaki, D, Yoshida, K, Wang, T, Komatsu, S, Fukumoto, T, Shuang, W, Xin, C, zhengshan, H, Shen, F, Vorobyov, N, Andreev, G, Martynova, N, Lyubinsky, A, Kubasov, A, Chen, J, Ma, N, Lu, Y, Zhao, J, Shahnazi, K, Lu, J, Jiang, G, Mao, J, Walser, M, Bojaxhiu, B, Kawashiro, S, Tran, S, Pica, A, Bachtiary, B, Weber, D, Gaito, S, Abravan, A, Richardson, J, Colaco, R, Saunders, D, Brennan, B, Petersen, I, Ahmed, S, Laack, N, Mizoe, J.E, Iizumi, T, Minohara, S, Kusano, Y, Matsuzaki, Y, Tsuchida, K, Serizawa, I, Yoshida, D, Katoh, H, Sakurai, H, Tujii, H, Kim, T.H, Park, J.W, Bo Hyun, K, Hyunjung, K, Sung Ho, M, Sang Soo, K, Sang Myung, W, Young-Hwan, K, Woo Jin, L, Dae Yong, K, Hong, Z, Wang, Z, Koroulakis, A, Molitoris, J, Kaiser, A, Hanna, N, Jiang, Y, Regine, W, DeCesaris, C.M, Choi, J.I, Carr, S.R, Burrows, W.M, Regine, W.F, Simone, C.B, Aihara, T, Hiratsuka, J, Kamitani, N, Higashino, M, Kawata, R, Kumada, H, Ono, K, Chou, Y.C, Dippolito, E, Bonora, M, Alterio, D, Gandini, S, Jereczeck, B.A, Kelly, C, Dobeson, C, Iqbal, S, Chatterjee, S, Hague, C, Li, T, Lin, A, Lukens, J, Slevin, N, Thomson, D, van Herk, M, West, C, Teo, K, Jeans, E, Manzar, G, Patel, S, Ma, D, Lester, S, Foote, R, Friborg, J, Jensen, K, Hansen, C.R, Andersen, E, Andersen, M, Eriksen, J.G, Johansen, J, Overgaard, J, Grau, C, Dědečková, K, Vítek, P, Ondrová, B, Sláviková, S, Zapletalová, S, Zapletal, R, Vondráček, V, Rotnáglová, E, Kwanghyun, J, Woojin, L, Dongryul, O, Yong Chan, A, Paudel, N, Schmidt, S, Ruckman, M, Gans, S, Stauffer, M, Helenowski, I, Patel, U, Samant, S, Gentile, M, Damico, N, Yao, M, Shuja, M, Routman, D.M, Foote, R.L, Garces, Y.I, Neben-Wittich, M.A, Patel, S.H, McGee, L.A, Harmsen, W.S, Ma, D.J, Sommat, K, Tong, A.K.T, Hu, J, Ong, A.L.K, Wang, F, Sin, S.Y, Wee, T.S, Tan, W.K, Fong, K.W, Soong, Y.L, Wallace, N, Fredericks, S, Fitzgerald, T, Vernimmen, F, Petringa, G, Cirrone, P, Agosteo, S, Attili, A, Cammarata, F.P, Cuttone, G, Conte, V, La Tessa, C, Manti, L, Rosenfeld, A, Lojacono, P.A, Hennings, F, Fattori, G, Peroni, M, Lomax, A, Hrbacek, J, Nguyen, H.G, Bach Cuadra, M, Sznitman, R, Schalenbourg, A, Pflaeger, A, Weber, A, Seidel, S, Stark, R, Heufelder, J, Mailhot Vega, R, Bradley, J, Lockney, N, Macdonald, S, Liang, X, Mazal, A, Mendenhall, N, Sher, D, Korreman, S.S, Andreasen, S, Petersen, J.B, Offersen, B.V, Gergelis, K, Jethwa, K, Whitaker, T, Shiraishi, S, Shumway, D, Press, R, Shelton, J, Zhang, C, Dang, Q, Tian, S, Shu, T, Seldon, C, Jani, A, Zhou, J, McDonald, M, Gort, E, Beukema, J.C, Spijkerman-Bergsma, M.J, Both, S, Langendijk, J.A, Matysiak, W.P, Brouwer, C.L, Baba, K, Numajiri, H, Murofushi, K, Oshiro, Y, Mizumoto, M, Onishi, K, Nonaka, T, Ishikawa, H, Okumura, T, Dominietto, M, Adam, K, Ahlhelm, F.J, Safai, S, Abdul-Jabbar, L, Song, J, Tseng, Y. D, Rockhill, J, Fink, J, Chang, L, Halasz, L. M, Guntrum, F, Steinmeier, T, Nagaraja, S, Jazmati, D, Geismar, D, Timmermann, B, Plaude, S, Lynch, C, Petras, K, Chang, J, Grimm, S, Lukas, R, Kumthekar, P, Merrell, R, Kalapurakal, J, Gross, J, Hoppe, B, Simone, C, Nichols, R.C, Pham, D, Mohindra, P, Chon, B, Morris, C, Li, Z, Flampouri, S, Powell, J.R, Murray, L, Burnet, N, Fernandez, S, Lingard, Z, McParland, L, O’Hara, D, Whitfield, G, Short, S.C, Guan, X, Gao, J, Hu, W, Yang, J, Xing, X, Hu, C, Kong, L, Zou, Z, Thomas, H, Sasidharan, B.K, Rengan, R, Zeng, J, Busold, S, Heese, J, Cerello, P, Bottura, L, Felcini, E, Ferrero, V, Monaco, V, Pennazio, F, de Rijk, G, Chang, H, KyungDon, C, Byunghun, H, Gyuseong, C, Chilukuri, S, Jalali, R, Panda, P.K, Korn, G, Larosa, G, Russo, A, Schillaci, F, Scuderi, V, Margarone, D, Fredén, E, Almhagen, E, Mejaddam, Y, Siegbahn, A, Guardiola, C, Gómez, F, Prieto-Pena, J, Fleta, C, De Marzi, L, Prezado, Y, Kabolizadeh, P, Reitemeier, P, Navin, M, Hamstra, D, Anderson, J, Stevens, C, Bartolucci, L, Adrien, C, Lejars, M, Vaillant, M, Fourquet, A, Robillard, M, Costa, E, Kirova, Y, Kolano, A.M, Degiovanni, A, Farr, J.B, Kundel, S, Pinto, M, Kurichiyanil, N, Würl, M, Englbrecht, F, Hillbrand, M, Schreiber, J, Parodi, K, Kurup, A, Magliari, A, Perez, J, Masui, S, Asano, T, Owen, H, Burt, G, Apsimon, R, Pitman, S, Popovici, M.A, Vasilache, R, Safavi-Naeini, M, Chacon, A, Howell, N, Middleton, R.J, Fraser, B, Guatelli, S, Rendina, L, Matsufuji, N, Gregoire, M.C, Sikora, K, Pettingell, J, Crocker, M, Saplaouras, A, Snijders, A, Mao, J.H, Nakamura, K, Bin, J, Gonsalves, A, Mao, H.S, Steinke, S, Roach, M, Leemans, W, Blakely, E, Takayama, K, Tan, T.S, Wee, J.T.S, Tuan, J.K.L, Wang, M.L.C, Quah, J.S.H, Tay, N.C.W, Lee, J.C.L, Lim, J.K.H, Oei, A.A, Tan, J.M, Park, S.Y, Chow, W.W.L, Omar, Y.B, Chew, P.G, Taylor, P, Lee, J, Tsurudome, T, Hirabayashi, M, Tsutsui, H, Yoshida, J, Takahashi, N, Kamiguchi, N, Hashimoto, A, Tachikawa, T, Mikami, Y, Kumata, Y, Wang, M, Chua, E.T, Wee, J, Wong, F.Y, Tuan, J, Master, Z, Wong, S, Welsh, J, Hentz, C, Pankuch, M, DeJongh, F, Xia, Y, Aitkenhead, A.H, Appleby, R, Merchant, M.J, MacKay, R.I, Young, H, Hughes, V, Alsulimane, M, Barajas, C.A, Taylor, J, Casse, G, Omar, A, Burdin, S, Boon, C, Lester, J, Thomas, A.J, Khan, A, Huthart, L, Leaver, K, Snell, J, Warlow, A, Burigo, L.N, Oborn, B, Belosi, F, Fredh, A, van de Water, S, Schneider, T, Patriarca, A, Bergs, J, Hierso, E, Hirayama, R, Martínez-Rovira, I, Seksek, O, Shirato, H, Nakamura, T, Ogino, T, Akimoto, T, Tamamura, H, Nishimoto, N, Proton-Net, G, Shimizu, S, Fabiano, S, Bangert, M, Guckenberger, M, Unkelbach, J, Mcauley, G, Teran, A, Slater, J, Wroe, A, Boon, I, Clorley, J, Owen, K, Oliver, T, Cicchetti, A, Ballarini, F, Rancati, T, Carrara, M, Zaffaroni, N, Bezawy, R. El, Carante, M, Valdagni, R, Faccini, R, Forte, G.I, Dhinsey, S, Greenshaw, T, Parsons, J, Welsch, C, Stock, M, Grevillot, L, Kragl, G, Carlino, A, Martino, G, Hug, E, Arya, H, Chirayath, V.A, Jin, M, Weiss, A.H, Glass, G.A, Chi, Y, Kaplan, L.P, Perez, R.A, Vestergaard, A, Gittings, E, Stamper, J, Beltran, C, Mark, P, Furutani, K, McAuley, G, Gordon, J, Boisseau, P, Dart, A, Nett, W, Kollipara, S, Grossmann, M, Actis, O, Diete, W, Rudolf, D, Klein, H.U, Kramert, R, Meer, D, Venkataraman, C, Waterstradt, T, Hérault, J, Bergerot, J.M, Hsi, W.C, Zhou, R, Zhang, X, Yang, F, Yinxiangzi, S, Sun, J, Li, X, Zhiling, C, Yuehu, P, Mengya, G, Haiyun, K, Qi, L, Zhentang, Z, Lin, Y.H, Tan, H.Q, Tan, L.K.R, Ang, K.W, Xiufang, L, Milkowski, K, Pang, D, Jones, M, Mizota, M, Tsunashima, Y, Himukai, T, Ogata, R, Uno, T, Ouyang, L, Jia, B, Li, D, Paul, K, Pullia, M, Savazzi, S, Lante, V, Foglio, S, Donetti, M, Falbo, L, Casalegno, L, Rousseau, M, Shinomiya, K, Yazawa, T, Iseki, Y, Kanai, Y, Hirata, Y, Powers, J, Solovev, A, Chernukha, A, Saburov, V, Shegai, P, Ivanov, S, Kaprin, A, Stolarczyk, L, Mojżeszek, N, Van Hoey, O, Farah, J, Domingo, C, Mares, V, Ploc, O, Trinkl, S, Harrison, R, Toltz, A, Nevitt, Z, Bloch, C, Taddei, P, Saini, J, Regmi, R, Yuntao, S, Jinxing, Z, Yap, J.S.L, Hentz, M, Silverman, J, Jolly, S, Boogert, S, Nevay, L, Kacperek, A, Schnuerer, R, Resta-Lopez, J, Zeng, X, Zheng, J, Li, M, Han, M, Song, Y, Holm, A, Korreman, S, Petersen, J.B.B, Bäumer, C, Fuenstes, C, Janson, M, Matic, A, Wulff, J, Psoroulas, S, Lomax, T, Arjomandy, B, Athar, B, Tesfamicael, B, Bejarano Buele, A, Deemer, J, Kozlyuk, V, VanSickle, K, Bolt, R, van Goethem, M.J, Langendijk, J, van t Veld, A, Chen, K.L, Wlodarczyk, B, Wu, H, Chen, Z, Shen, L, Fachouri, N, Placidi, L, Böhlen, T, Ieko, Y, Iwai, T, Nemoto, K, Suzuki, K, Kanai, T, Miyasaka, Y, Harada, M, Yamashita, H, Kubota, I, Kayama, T, Jensen, M.F, Bræmer-Jensen, P, Randers, P, Søndergaard, C.S, Nørrevang, O, Taasti, V.T, Kong, H, Yin, C, Gu, M, Liu, M, Shu, H, Chongxian, Y, Haiyang, Z, Juan, Z, Ming, L, Manzhou, Z., Liying, Z, Kecheng, C, Xiaolei, D, Castro, J, Freire, J, Cremades, M, Moral, L, Rico, P, Ares, C, Miralbell, R, Shi, J, Xia, J, Wang, B, Li, Q, Liu, X, Sung, C.C, Chen, W.P, Liao, T.Y, Takashina, M, Hamatani, N, Tsubouchi, T, Yagi, M, Mizoe, J, Titt, U, Mirkovic, D, Yepes, P, Wang, Q, Grosshans, D, Wieser, H.P, Mohan, R, Vadrucci, M, Xiao, G, Cai, X, Li, G, Yuan, Y, Lu, R, Sun, G, Zhang, M, Deming, L, lianhua, O, Takada, K, Tanaka, S, Matsumoto, Y, Naito, F, Kurihara, T, Nakai, K, Matsumura, A, Sakae, T, Shamurailatpam, D, P, K, Mp, N, A, M, Kg, G, T, R, C, S, J, R, Rozes, A, Dutheil, P, Batalla, A, Vela, A, Rana, S, Bennouna, J, Gutierrez, A, He, P, Shen, G, Dai, Z, Ma, Y, Chen, W, Pandey, J, Chirvase, C, Osborne, M, Ilsley, E, Di Biase, I, Kato, T, Hirose, K, Arai, K, Motoyanagi, T, Harada, T, Takeuchi, A, Kato, R, Tanaka, H, Mitsumoto, T, Takai, Y, Bolsa-Ferruz, M, Palmans, H, Chen, Y.S, Wu, S.W, Huang, H.C, Wang, H.T, Yeh, C.Y, Chen, H.H, Cook, H, Lourenço, A, Dal Bello, R, Magalhaes Martins, P, Hermann, G, Kihm, T, Seimetz, M, Brons, S, Seco, J, De Saint-Hubert, M, Swakon, J, De Freitas Nascimento, L, Tessaro, V.B, Poignant, F, Gervais, B, Beuve, M, Galassi, M.E, Harms, J, Chang, C.W, Zhang, R, Lin, Y, Langen, K, Liu, T, Lin, L, Howard, M, Denbeigh, J, Remmes, N, Debrot, E, Herman, M, Huang, Y.Y, Tsai, S.H, Fang, F.M, Mizuno, H, Sagara, T, Yamazaki, Y, Kato, M, Oyama, S, Pembroke, C, Joslin-Tan, T, Maggs, R, O’Neil, K, Barrett-Lee, P, Staffurth, J, Resch, A, Heyes, P, Georg, D, Fuchs, H, Hideyuki, M, katsuhisa, N, Wataru, Y, Samnøy, A.T, Ytre-Hauge, K.S, Povoli, M, Kok, A, Summanwar, A, Linh, T, Malinen, E, Röhrich, D, Asp, J, Santos, A, Afshar, V.S, Zhang, W.Q, Bezak, E, a, M, k, G, p, K, mp, N, t, R, c, S, j, R, Smith, B, Hammer, C, Hyer, D, DeWerd, L, Culberson, W, Brooke, M, Straticiuc, M, Craciun, L, Matei, C.E, Radu, M, Xiao, M, Paschalis, S, Joshi, P, Price, T, Mehta, M, Graça, J, Biglin, E, Aitkenhead, A, Price, G, Williams, K, Chadwick, A, Schettino, G, Robinson, A, Kirkby, K, Catanzano, D, Cessac, R, Rutherford, R, Ahmed, A, Mohammadi, A, Tashima, H, Yamaya, T, Chavez Barajas, C, Taylor, A, Vossebeld, J, Barwick, I, CHEON, W, Jo, K, Ahn, S.W, Cho, J, Han, Y, Choi, H.H.F, Cheung, C.W, Cohilis, M, Lee, J.A, Sterpin, E, Souris, K, Mundy, D, Petasecca, M, Rosenfeld, A.B, Boso, A, Di Fulvio, A, Becchetti, F.D, Torres-Isea, R.O, Febbraro, M, Gagnon-Moisan, F, Feng, Y, Fontana, M, Etxebeste, A, Dauvergne, D, Letang, J.M, Testa, E, Sarrut, D, Maxim, V, Gajewski, J, Durante, M, Garbacz, M, Krah, N, Krzempek, K, Schiavi, A, Skrzypek, A, Tommasino, F, Ruciński, A, Gillin, M, Sahoo, N, Zhu, X.R, Van Delinder, K.W, Crawford, D, Khan, R, Gräfe, J, Kakiuchi, G, Shioyama, Y, Shimokomaki, R, Huang, Z, Wang, W, Sheng, Y, Lee, M.W, Jan, M.L, Hong, J.H, Okamoto, K, Sato, H, Kalantan, S, Boston, A, Kang, Y, Shen, J, Casey, W, Vern-Gross, T, Wong, W, McGee, L, Halyard, M, Keole, S, Kelleter, L, Radogna, R, Saakyan, R, Basharina-Freshville, A, Attree, D, Volz, L, Komenda, W, Krzempek, D, Mierzwińska, G, Barbara, M, Kopeć, R, Lan, J.H, Chang, F.X, Lin, C.H, Lee, T.F, Ahn, S, Cheon, W, Lee, M, Letellier, V, Osorio, J, Dreindl, R, Livingstone, J, Gallin-Martel, M.L, Létang, J.M, Marcatili, S, Morel, C, Maggi, P, Chen, H, Yang, H, Panthi, R, Mackin, D, Peterson, S, Beddar, S, Polf, J, Masuda, T, Nishio, T, Sano, A, Tomozawa, H, Nishio, A, Tsuneda, M, Okamoto, T, Karasawa, K, Miszczynska Giza, O, Sánchez-Parcerisa, D, Herraiz, J. L, Rojo-Santiago, J, Udias, J.M, Mitrović, U, Hager, M, List, I, Fischer, C, Cecowski, M, Gajšek, R, Mizutani, S, Hotta, K, Baba, H, Tanizaki, N, Yamaguchi, T, Moon, S.Y, Rah, J.E, Yoon, M, Shin, D, Nebah, P, Dugas, J, Syh, J, Maynard, M, Marsh, N, Rosen, L, Nichiporov, D, Watts, D.A, Chen, Y, Petterson, M, Lee, W.D, Penfold, S.N, Ruebel, N, Piersimoni, P, Mille, M, Mossahebi, S, Chen-Mayer, H, Allport, P, Green, S, Shaikh, S, Walker, D, Qamhiyeh, S, Levegruen, S, Kutscher, S, Kranke, H, Olbrich, G, Stuschke, M, Baran, J, Pawlik-Niedzwiecka, M, Moskal, P, Rutherford, H, Poenisch, F, Martin, C, Wu, R, Mayo, L.L, Shah, S.J, Frank, S.J, Gunn, G.B, Sakurai, Y, Takata, T, Kondo, N, Schlegel, N, Deng, Y, Sun, W, Wu, X, Yap, J, Zhang, H, Szumlak, T, Schuy, C, Simeonov, Y, Zink, K, Graeff, C, Weber, U, Allred, B, Robertson, D, Dewees, T, Gagneur, J, Stoker, J, Stützer, K, Valentini, C, Agolli, L, Hölscher, T, Thiele, J, Dutz, A, Löck, S, Krause, M, Baumann, M, Richter, C, Takayanagi, T, Uesaka, T, Nakamura, Y, Unlu, M.B, Kuriyama, Y, Uesugi, T, Ishi, Y, Umegaki, K, Matsuura, T, Watts, D. A, Huisman, B, Valladolid Onecha, V, Fraile, L.M, Sanchez Parcerisa, D, España, S, Ze, W, Chen, H.Y, Chuang, K.S, Wilson, M, Lui, J, Noble, D, Holloway, S, Yap, J.H.H, Chew, M.M.L, Pang, P.P, Lim, C.J.C, Gan, S.A, Tan, T.W.K, Shen, Z.M, Moyers, M, Qianxia, W, Chen, H.L, Li, J, Lin, J, Zhao, L, Myers, W, Ates, O, Faught, J, Yan, Y, Faught, A, Sobczak, D, Hua, C.H, Moskvin, V, Merchant, T, Henkner, K, Ecker, S, Chaudhri, N, Ellerbrock, M, Jäkel, O, Hernandez Morales, D, Augustine, K, Johnson, J, Younkin, J, Fiorina, E, Mattei, I, Morrocchi, M, Sarti, A, Traini, G, Valle, S.M, Bert, C, Karger, C.P, Kamada, T, Scholz, M, DeLuca, P.M, De Simoni, M, Dong, Y, Embriaco, A, Fischetti, M, Mancini-Terracciano, C, Mirabelli, R, Muraro, S, Lens, E, de Blécourt, A, Schaart, D, Vos, F, van Dongen, K, Berthold, J, Khamfongkhruea, C, Petzoldt, J, Wohlfahrt, P, Pausch, G, Janssens, G, Smeets, J, Shamblin, J, Blakey, M, Moore, R, Matteo, J, Schreuder, N, Derenchuk, V, Shin, J, Jee, K.W, Clasie, B.M, Depauw, N, Batin, E, Madden, T.M, Schuemann, J, Paganetti, H, Kooy, H.M, Daniel, M, Abbassi, L, Arsène-Henry, A, Amessis, M, Maes, S, O’Ryan-Blair, A, Laval, G, Ermoian, R, Taddei, P. J, Andersson, K, Norrlid, O, Lindbäck, E, Vallhagen Dahlgren, C, Witt Nyström, P, Argota Perez, R, Sharma, M.B, Elstrøm, U.V, Bizzocchi, N, Albertini, F, Branco, D, Kry, S, Rong, J, Frank, S, Followill, D, Busch, K, Muren, L.P, Thörnqvist, S, Andersen, A.G, Pedersen, J, Dong, L, Cao, W, Bai, X, Van Lobenstein, N, Traneus, E, Anson, C, Comi, S, Marvaso, G, Russo, S, Giandini, T, Avuzzi, B, Ciardo, D, Cattani, F, Jereczek-Fossa, B, Cotterill, J, Esposito, M, Winter, A, Allinson, N, Liu, G, Yan, D, Jawad, S, Dilworth, J, Chen, P, Ackermann, B, Florijn, M, Sharfo, A.W.M, Wiggenraad, R.G.J, van Santvoort, J.P.C, Petoukhova, A.L, Hoogeman, M.S, Mast, M.E, Dirkx, M.L.P, Fujitaka, S, Fujii, Y, Nihongi, H, Nakayama, S, Ho, M.W, Artz, M, Tong, K.T.A, Hytonen, R, Koponen, T, Niemela, P, Iancu, G, Lautenschlaeger, S, Eberle, F, Horst, F, Ringbaek, T, Engenhart-Cabillic, R, Kim, M.J, Hong, C.S, Kim, Y.B, Park, S.H, Kim, J.S, Reiterer, J, Steffal, C, Gora, J, Kann, T, Schratter-Sehn, A.U, Li, H, Chen, M, wu, R, Li, Y, zhang, X, Gautam, A, poenisch, F, sahoo, N, Zhu, R, Lin, M, Chang, J.T.C, Maeda, Y, Sato, Y, Shibata, S, Bou, S, Yamamoto, K, Sasaki, M, Fuwa, N, Takamatsu, S, Kume, K, Lim, F, Faller, F, Stiller, W, Ming, X, Hui, H, Mukawa, T, Takashi, Y, Stephenson, L, Pang, E.P.P, Paz, A.E, Yoshida, Y, Righetto, R, Vecchi, C, Alparone, A, De Spirito, M, Radhakrishnan, S, Chandrashekaran, A, Nandigam, J, Sarma, Y, Rechner, L, Munck af Rosenschöld, P, Bäck, A, Johansen, T.S, Schut, D.A, Aznar, M.C, Nyman, J, Ren, X, Rosas, S, Vanderstraeten, R, Jyske, T, Jari, L, Yuenan, W, Henthorn, N, Warmenhoven, J, Merchant, M, Kirkby, N, Ranald, M, Stefanowicz, S, Zschaeck, S, Troost, E.G.C, Stubington, E, Ehrgott, M, Nohadani, O, Shentall, G, Sun, T, yin, Y, Lin, X, Yoshimura, T, Matsuo, Y, Yamazaki, R, Takao, S, Miyamoto, N, Toussaint, L, Indelicato, D.J, Lassen-Ramshad, Y, Kirby, K, Mikkelsen, R, Di Pinto, M, Høyer, M, Stokkevåg, C.H, Van Herk, M, Shortall, J, Green, A, Vasquez Osorio, E, Mackay, R, Navratil, M, Andrlik, M, Chiang, Y.Y, Yeh, Y.H, Yeh, Y.J, Chang, T.C, Eaton, B, Yang, X, Esiashvili, N, Gu, W, Ruan, D, O’Connor, D, Zou, W, Tsai, M.Y, Jia, X, Sheng, K, Hyde, C, Chen, P.Y, Deraniyagala, R, Petoukhova, A, Klaassen, L, Habraken, S, Jacobs, J, Sattler, M, Verhoeven, K, Klaver, Y, Widesott, L, Fracchiolla, F, Algranati, C, Scifoni, E, Scartoni, D, Farace, P, Kröniger, K, Bauer, J, Nilsson, R, Chen, X, Liu, R, Sun, B, Mutic, S, Zhang, T, Zhao, T, Kajdrowicz, T, Wochnik, A, Swakoń, J, Małecki, K, Michalec, B, Moffitt, G, Wootton, L, Hardemark, B, Sandison, G, Emery, R, Stewart, R, Reidel, C.A, Finck, C, Deisher, A, Mahajan, A, Michael, H, Ahn, S.H, Kwang Hyeon, K, Chankyu, K, Youngmoon, G, Shinhaeng, C, Se Byeong, L, Young Kyung, L, Haksoo, K, Dongho, S, Jong Hwi, J, Ali, Y, Monini, C, Maigne, L, Alshaikhi, J, D’Souza, D, Amos, R. A, Baumann, K.S, Gomà, C, Flatten, V, Lautenschläger, S, Abdel-Rehim, A, Wan Chan Tseung, H.S, Ma, J, Kamal Syed, H, Boscolo, D, Krämer, M, Fuss, M, Braunroth, T, Rabus, H, Baek, W.Y, Brown, H, Alshammari, H, Brownstein, J, Giantsoudi, D, Wang, C.C, Grassberger, C, Chen, C, Chan, M.F, Mah, D, Hojo, Y, Xu, C, Elia, A, Fung, A, Nguyen, B.N, Oyervides, M, Koska, B, Kamal Sayed, H, Kim, C, Kim, Y.J, Lee, S.B, Goh, Y, Cho, S, Jeong, J.H, Kim, H, Lim, Y.K, Koh, W.Y.C, Lew, W.S, Lee, C.L.J, Kollitz, E, Han, H, Kim, C.H, Kroll, C, Riboldi, M, Newhauser, W, Dedes, G, Fuglsang Jensen, M, Nyström, U.H, Skyt, P.S, Hoffmann, L, Sloth Møller, D, Dokic, I, Kuo, S.H, Tai, P.L, Cheng, S.W, Chong, N.S, Yeom, Y.S, Kuzmin, G, Griffin, K, Langner, U, Jung, J.W, Lee, C, Lee, C.C, Hsu, W, Chao, T.C, Liamsuwan, T, Pischom, N, Tangboonduangjit, P, Suchada, T, Zheng, D, Rutenberg, M, Dhabaan, A, Harrabi, S, MARAFINI, M, Gioscio, E, Yunsheng, D, Alphonse, G, Rodriguez Lafrasse, C, Testa, É, Morris, B, Asavaphatiboon, S, DeBlois, D, Yam, M, Sękowski, P, Skwira-Chalot, I, Matulewicz, T, Flynn, R, Verbeek, N, Smyczek, S, Brualla, L, Lei, Y, Ghavidel, B, Curran, W, Beitler, J, Yu, H.W, Jeng, S.C, Tsai, Y.C, Chiou, J.F, Yusa, K, Dai, T, Yuan, P, Shafai-Erfani, G, Shu, H.K, Pepin, M, Tryggestad, E.J, Abdel Rehim, A, Johnson, J.E, Herman, M.G, Lee, S.C, Sheu, R.J, Ödén, J, Ramos-Mendez, J, Perl, J, Faddegon, B, Alaka, B.G, Bentefour, E.H, Samuel, D, Biradar, B, Frusti, P, Den Otter, L.A, Kurz, C, Stanislawski, M, Landry, G, Meijers, A, Knopf, A.C, Dickmann, J, Wesp, P, Rit, S, Johnson, R.P, Bashkirov, V, Schulte, R.W, Hoyle, B, Johnson, R, Schulte, R, Weller, J, Cotterill, J.V, Waltham, C, Allport, P.P, Taylor, M, Rogers, J, Evans, P.M, Allinson, N.M, Henry, T, Ardenfors, O, Gudowska, I, Poludniowski, G, Dasu, A, Lai, Y, Yuncheng, Z, Yiping, S, Mingwu, J, Xun, J, Yujie, C, Meric, I, Mattingly, J, Moustafa, A, Skjerdal, K, Moteabbed, M, Harisinghani, M, Efstathiou, J.A, Lu, H.M, Kabuki, S, Mizowaki, T, Ofierzynski, R, Paysan, P, Strzelecki, A, Lucca, R, Patch, S, Mustapha, B, Santiago-Gonzalez, D, Pettersen, H.E.S, Sølie, J, Levegrün, S, Pöttgen, C, Meyer, E, Collins-Fekete, C.A, Bashkirov, V.A, Wang, Y.M, Sung, K.C, Wang, C.J, Wu, H.Y, Winter, M, Bauer, U, Hansmann, T, Naumann, J, Peters, A, Pilz, K, Troost, E, Yan, S, Greenhalgh, J, Li, S, Bortfeld, T, Flanz, J, Ytre-Hauge, K, Zhang, L, Sharp, G.C, Cascio, E.W, Flanz, J.B, Tang, J, Zhu, J, Zhang, J, Uh, J, Sarosiek, C, Ricci, J, Coutrakon, G, Ozoemelam, I, van der Graaf, E.R, Maciej, K, Zhang, N, Brandenburg, S, Dendooven, P, Niepel, K, Yohannes, I, Dietrich, O, Ertl-Wagner, B, Pappas, E, Sølie, J.R, Odland, O.H, Ghesquiere-Dierickx, L.M.H, Felix Bautista, R, Gehrke, T, Jakubek, J, Turecek, D, Martisikova, M, Malekzadeh, E, Rajabi, H, Kalantari Mahmoudabadi, F, Meschini, G, d’Arenzo, D, Comini, D, Huynh, M.T, Paganelli, C, Fontana, G, Mancin, A, Preda, L, Su, Z, Henderson, R, Nichols, C, Bryant, C, Mendenhall, W, Boyer, B, Geerebaert, Y, Gevin, O, Koumeir, C, Magniette, F, Manigot, P, Poirier, F, Servagent, N, Thiebaux, C, Verderi, M, Chen, Y.R, Anderle, K, Jeraj, R, Chuter, R, Allan, I, Patel, I, MacKay, R, Harrison, K, Hoole, A, Thomas, S, Jena, R, Liao, Z, Zhu, R.X, Freeman, M, Espy, M, Aulwes, E, Magnelind, P, Merrill, F, Neukirch, L, Sidebottom, R, Tang, Z, Tupa, D, Wilde, C, Shusharina, N, Fullerton, B, Adams, J, Sharp, G, Chan, A, Dolde, K, Naumann, P, Dávid, C, Kachelrieß, M, Saito, N, Pfaffenberger, A, Wolf, M, Lis, M, Moreau, J, Buttion, M, Molitoris, J.K, Simone-, C.B, Regele, H, Bula, C, Danuser, S, Kang, M, Lin, H, Ribeiro, C. O, Dumont, D, Terpstra, J, Knopf, A, Wagenaar, D, Kierkels, R, van der Schaaf, A, Scandurra, D, Sijtsema, M, Korevaar, E, van den Hoek, A, O’Neil, M, Chung, H, Sala, I, Ramirez, H, Guerrero, T, Mondlane, G, Butkus, M.B, Stewart, R.D, Carlson, D.J, Ingram, S, Ytre-Hauge, K. Smeland, Rørvik, E, Perales, A, Carabe, A, Baratto-Roldan, A, Kimstrand, P, Cortes-Giraldo, M, Bertolet, A, Barato-Roldan, A, Baiocco, G, Barbieri, S, Mei, Z, Fan, K, Tang, K, Wang, J, Zhu, H, Sung, W, McNamara, A, Tran, L.T, Qi, Y, Xu, X, Pei, X, Chiang, Y, Chien-Hau, C, Chung-Chi, L, Chuan-Jong, T, Tsi-Chian, C, Wang, L, Cao, J, Wang, X, Lin, E, Minami, K, Kondo, R, Khoei, S, Shirvalilou, S, Khoee, S, Jamali Raoufi, N, Karimi, M.R, Shakeri-Zadeh, A, Patera, V, Rinaldi, I, Sas-Korczynska, B, Deng, W, Karagounis, I, Huynh, K, Maity, A, Abel, E, Santa Cruz, G, Monti Hughes, A, Herrera, M, Trivillin, V, Portu, A, Garabalino, M, Schwint, A, Gonzalez, S, Saint Martin, G, Santa Cruz, I, Tamari, Y, Watanabe, T, Masunaga, S.I, Wittig, A, Nigg, D, Stecher-Rasmussen, F, Moss, R, Igawa, K, Akita, K, Akabori, K, Hattori, K.J, Arima, H, Motoyama, K, Higashi, T, Trivillin, V.A, Pozzi, E.C.C, Thorp1, S.I, Curotto1, P, Garabalino1, M.A, Itoiz, M.E, Santa Cruz, I.S, Ramos, P.S, Palmieri, M.A, Schwint, A.E, Gadan, M.A, Thorp, S.I, Curotto, P, Portu, A.M, Thorp, S, Trivillin, V. A, Schwint, A. E, Fukuo, Y, Kanemitsu, T, Fukumura, M, Kosaka, T, Hiramatsu, R, Kuroiwa, T, Miyatake, S, Kawabata, S, Kirihata, M, Goldfinger, J.A, Garabalino, M.A, Pozzi, E.C, Ramos, P, De Leo, L.N, Yu, Q, Engelbrecht, M, Sioen, S, Miles, X, Nair, S, Ndimba, R, Baeyens, A, Vandevoorde, C, Buizza, G, Meng, J, Takai, N, Ogami, M, Nakamura, S, Ohba, Y, Liu, R.F, Zhang, Q.N, Wang, X.H, Luo, H.T, Kong, Y.R, Jansen, J, Tirinato, L, Marafioti, M.G, Hanley, R, Yao, X.Q, Pagliari, F, Huang, C.Y, Wong, W.K.R, Ho, Y.W, Nam, P.H, Koryakin, S.N, Troshina, M.V, Koryakina, E.V, Potetnya, V.I, Baykuzina, R.M, Lychagin, A.A, Ulyanenko, S.E, Molinelli, S, Giuseppe, M, Tran, L, Bolst, D, James, B, Steinsberger, T, Alliger, C, Dahle, T.J, Rusten, E, Wright, P, Forsback, S, Silvoniemi, A, Minn, H, Andersson, S, Buti, G, Barragán Montero, A.M, Vasquez-Osario, E, Sabouri, P, Nkenge, K, Yi, B, Burigo, L, Greilich, S, Thomas, R, Clark, C, Lourenco, A, Oancea, C, Granja, C, Kodaira, S, Coplan, M, Graybill, J, Lutz, L, Shahi, C, Su, J.J, Thompson, A, Romano, F, Shipley, D, Hong, T.S, Labarbe, R, Wolfgang, J.A, Meyer, S, Bortfeldt, J, Lämmer, P, Schnürle, K, Peters, N, Möhler, C, Hofmann, C, Koschik, A, Bryce-Atkinson, A, Van Nugteren, J, De Rijk, G, Kirby, G, Dutoit, B, Vignati, A, Ahmadi Ganjeh, Z, Fausti, F, Giordanengo, S, Hammad Ali, O, Sacchi, R, Shakarami, Z, Cirio, R, Inoue, J, Tachibana, M, Shimizu, Y, Ochi, T, Amano, D, Miyashita, T, Cooley, J, Nyamane, S, Zwart, T, Wagner, M, Lu, M, Rosenthal, S, Hashimoto, T, Katoh, N, Tamura, H, Emert, F, Missimer, J, Eichenberger, P, Gmuer, C, Spengler, C, Kamp, F, Hofmaier, J, Reiner, M, Belka, C, Van Ooteghem, G, Dasnoy-Sumell, D, Geets, X, Chen, C.C, Galbreath, G, Shmulenson, R, Pinheiro de Almeida, I, van Elmpt, W, Vilches Freixas, G, Unipan, M, Verhaegen, F, Bosmans, G, Garcia, G, Cevallos Robalino, L, Guzman-Garcia, K, Vega-Carrillo, H.R, Gomez-Ros, J.M, Gallego, E, Hintenlang, K, Martin, M, Gupta, N, Meissner, J, Smathers, J, Ainsley, C, Yin, L, Jagt, T, Breedveld, S, van Haveren, R, Nout, R, Astreinidou, E, Staring, M, Heijmen, B, Hoogeman, M, Stokes, W, Matter, M, Nenoff, L, Toramatsu, C, Wakizaka, H, Nitta, M, Nishikido, F, Hirano, Y, Yoshida, E, Miller, J, Maris, A, Kalle, R, Franco, G, Kierkels, R.G.J, van den Hoek, J.G.M, Bijl, H.P, Dieters, M, Steenbakkers, R.J.H.M, Dejongh, F, DeJongh, E, Rykalin, V, Karonis, N, Ordonez, C, Duffin, K, Winans, J, Neph, R, Sanchez-Parcerisa, D, Lopez-Aguirre, M, Dolcet Llerena, A, Udias, J, Oxley, D, Besson, R, Meier, G, Nanz, A, Schorta, M, Fleury, E, Trnková, P, Erdal, E, Hassan, K, Beenakker, J.W, Pignol, J.P, Matysiak, W, Tian, L, Zepter, S, Winterhalter, C, Shim, S, Gouldstone, C, Trnkova, P, Vatnitsky, S, Liu, K, Li, E, Zhuangming, S, Lowenstein, J, De Wilde, O, Bossier, V, Lerot, X, Pouppez, A, Xx, X, Verburg, J, Hueso-Gonzalez, F, Ruggieri, T, Amato, C, Ghesquiere-Dierickx, L, Felix-Bautista, R, Deville, C, Barsky, A, Vapiwala, N, Mohamad, O, Tabuchi, T, Nitta, Y, Nomoto, A, Kasuya, G, Choy, H, Miyashiro, I, Bush, D, Chuong, M, Kozarek, J, Rubens, M, Larson, G, Vargas, C, Hung, S.P, Hsieh, C.E, Huang, B.S, Tsang, N.M, Smith, N, Viehman, J, Harmsen, W, Elswick, S, Boughey, J, Harless, C, Jimenez, R, Hickey, S, DePauw, N, Ho, A, Taghian, A, MacDonald, S, Meek, A, Hedrick, S, Baliga, S, Gallotto, S, Lewy, J, Patteson, B, Speroni, S, Omsberg, A, Tarbell, N, Musolino, P, Yock, T, Indelicato, D, Rotondo, R, Mailhot, R, Uezono, H, Bradfield, S, Agarwal, V, Gillies, C, Gosling, A, Casares-Magaz, O, Eskildsen, S.F, Lassen, Y, Hasle, H, Tofting-Olesen, K, Alapetite, C, Puget, S, Nauraye, C, Beccaria, K, Bolle, S, Doz, F, Sainte-Rose, C, Bouffet, E, Zerah, M, Wu, J, Qiu, X, Hua, W, Mao, Y, Frakulli, R, Kramer, P.H, Glas, M, Blase, C, Tippelt, S, Konrath, L, Gruber, N, Schallerbauer-Peter, A, Mock, U, Niyazi, M, Niemierko, A, Schapira, E, Kim, V, Oh, K.S, Hwang, W.L, Busse, P.M, Loeffler, J.S, Shih, H.A, Appel, H, Tseng, Y.D, Tsai, H, Sinesi, C, Rossi, C, Badiyan, S, Kotecha, R, Pike, L, Horick, N, Yeap, B, Franck, K, Wang, I, Loeffler, J, McKenna, M, Shih, H, Kountouri, M, Kole, A.J, Murray, F.R, Kliebsch, U, Combescure, C, iannalfi, A, Riva, G, Dougherty, J, Kruse, J, Iott, M, Brown, P, Olivier, K, Brodin, P, Kabarriti, R, Schechter, C, Kalnicki, S, Garg, M, Tomé, W, Lu, J.J, Chen, P.J, Dhanireddy, B, Severo, C, Lee, C.H, Lin, C.R, Rosier, L, Mathis, T, DeLaney, T, Lin, S, O’Meara, E, Powell, T, Hong, T, Hall, D, Liu, A, Ntentas, G, Dedeckova, K, Darby, S, Cutter, D, Zapletalova, S, Chen, Y.L, Miao, R, Lee, H, Hsiao-Ming, L, Choy, E, Cote, G, Eulitz, J, Lutz, B, Enghardt, W, Lühr, A, Mcmahon, S, Prise, K, Sung Hyun, L, Tansho, R, Mizushima, K, Warmenhoven, J.W, Hufnagl, A, Friedrich, T, Deycmar, S, Gruber, S, Dörr, W, Pruschy, M, Waissi, W, Burckel, H, Nicol, A, Noel, G, Yousef, I, Koizumi, M, Santa Cruz, G.A, González, S.J, Longhino, J, Provenzano, L, Oña, P, Rao, M, Cantarelli, M.D.L.Á, Leiras, A, Olivera, M.S, Alessandrini, P, Brollo, F, Boggio, E, Costa, H, Ventimiglia, R, Binia, S, Nievas, S.I, Langle, Y, Eijan, A.M, Colombo, L.L, Kawai, K, Nakamura, H, Natsuko, K, Masaki, H, Nakada, M, Furuse, M, Miyatake, S.I, Koivunoro, H, Kankaanranta, L, González, S, Joensuu, H, Sokol, O, Hild, S, Wiedemann, J, Köthe, A, Perry, D, Batie, M, Mascia, A, Sertorio, M, Luhr, A, Suckert, T, Müller, J, Beyreuther, E, Gotz, M, Haase, R, Schürer, M, Tillner, F, von Neubeck, C, Davis, A, Sishc, B, Saha, J, Ding, L, Story, M, Wagner, S, Kim, S.Y, Geary, S, Woodruff, T, Xu, T, Meng, Q, Gilchrist, S, Perentesis, J.P, Zheng, Y, Wells, S.I, Kong, Y, Liu, Y, Geng, Y, Knoll, M, Schwager, C, Schlegel, J, Schnölzer, M, Ding, L.H, Aroumougame, A, Chen, B, Saha, D, Pompos, A, Carter, R, Nickson, C, Thomson, J, Hill, M, Rodrigues, D, Snider, J, Sharma, A, Zakhary, M, Kara, L, Vujaskovic, Z, Dykstra, M, Best, T, Keane, F, Khandekar, M, Fintelmann, F, Willers, H, Singh, P, Eley, J, Malyapa, R, Mahmood, J, Hårdemark, B, Sandison, G.A, Wootton, L.S, Miyoaka, R.S, Laramore, G.E, Yang, P, van der Weide, H, Maduro, J, Heesters, M, Gawryszuk, A, Davila-Fajardo, R, Langendijk, H, Eckhard, M, Maxwell, A, VanNamen, K, Cashin, M, Jacovic, A, Dunn, M, kim, T, Jung, J, Kim, J, Swerdloff, S, Saunders, A, Thomas, J, Kidani, T, Okada, A, Tomida, K, Pennington, H, Xiaoqiang, L, Weigang, H, An, Q, Di, Y, Craig, S, Inga, G, Peyman, K, Xuanfeng, D, Cunningham, C, de Kock, M, Slabbert, J, Panaino, C.M, Phoenix, B, Regan, P.H, Shearman, R, Collins, S.M, Taylor, M.J, Grayson, M, Kato, K, Choi, H, Jang, J.W, Shin, W.G, Min, C.H, McMahon, S, Padilla Cabal, F, Fragoso, J.A, Resch, A.F, Katsis, A, Girdhani, S, Marshall, A, Jackson, I, Bentzen, S, Parry, R, Gantz, S, Schellhammer, S, Hoffmann, A, Delorme, R, Dos Santos, M, Salmon, R, Öden, J, Bullivant, K, Rucksdashal, R, Ferret, E, Covington, F, Rice, S, Decesaris, C, Siddiqui, O, Kowalski, E, Samanta, S, and Rothwell, B
- Subjects
Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0642 ,Physics: Absolute and Relative DosimetryPTC58-0180 ,Biology: Biology and Clinical InterfacePTC58-0685 ,Physics: Commissioning New FacilitiesPTC58-0385 ,Physics: 4D Treatment and DeliveryPTC58-0546 ,Clinics: EyePTC58-0714 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0528 ,Physics: Quality Assurance and VerificationPTC58-0507 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0661 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0221 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0531 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0653 ,Biology: Drug and Immunotherapy CombinationsPTC58-0163 ,Clinics: Sarcoma - LymphomaPTC58-0055 ,Biology: Drug and Immunotherapy CombinationsPTC58-0166 ,Clinics: CNS / Skull BasePTC58-0198 ,Physics: Treatment PlanningPTC58-0421 ,Clinics: PediatricsPTC58-0560 ,General: New HorizonsPTC58-0709 ,Physics: Treatment PlanningPTC58-0664 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0286 ,Physics: Treatment PlanningPTC58-0666 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0346 ,Physics: Treatment PlanningPTC58-0547 ,Physics: Treatment PlanningPTC58-0308 ,Physics: Treatment PlanningPTC58-0549 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0111 ,Physics: Absolute and Relative DosimetryPTC58-0050 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0587 ,Biology: Biology and Clinical InterfacePTC58-0454 ,Physics: Absolute and Relative DosimetryPTC58-0052 ,Physics: Commissioning New FacilitiesPTC58-0395 ,Physics: 4D Treatment and DeliveryPTC58-0534 ,Physics: Dose Calculation and OptimisationPTC58-0072 ,Physics: 4D Treatment and DeliveryPTC58-0533 ,Physics: 4D Treatment and DeliveryPTC58-0538 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0113 ,Physics: Quality Assurance and VerificationPTC58-0633 ,Physics: Treatment PlanningPTC58-0431 ,Physics: Beam Delivery and Nozzle DesignPTC58-0230 ,Biology: Mathematical Modelling SimulationPTC58-0179 ,Clinics: Head and Neck / EyePTC58-0365 ,Physics: Treatment PlanningPTC58-0319 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0697 ,Biology: Biology and Clinical InterfacePTC58-0663 ,Physics: Commissioning New FacilitiesPTC58-0240 ,Physics: Adaptive TherapyPTC58-0177 ,Physics: Commissioning New FacilitiesPTC58-0363 ,Physics: Commissioning New FacilitiesPTC58-0487 ,Physics: 4D Treatment and DeliveryPTC58-0209 ,Physics: 4D Treatment and DeliveryPTC58-0206 ,Clinics: CNS / Skull BasePTC58-0294 ,Physics: Commissioning New FacilitiesPTC58-0127 ,Biology: Mathematical Modelling SimulationPTC58-0068 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0062 ,Physics: 4D Treatment and DeliveryPTC58-0692 ,Physics: Quality Assurance and VerificationPTC58-0723 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0494 ,Physics: Treatment PlanningPTC58-0643 ,Physics: Treatment PlanningPTC58-0521 ,Physics: Treatment PlanningPTC58-0402 ,Physics: Treatment PlanningPTC58-0405 ,Clinics: Head and Neck / EyePTC58-0273 ,Clinics: GIPTC58-0397 ,Physics: Treatment PlanningPTC58-0648 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0489 ,Physics: Quality Assurance and VerificationPTC58-0617 ,Physics: Quality Assurance and VerificationPTC58-0616 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0668 ,Clinics: CNS / Skull BasePTC58-0188 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0625 ,Physics: Treatment PlanningPTC58-0654 ,Physics: Treatment PlanningPTC58-0655 ,Biology: Drug and Immunotherapy Combinations Poster Discussion SessionsPTC58-0133 ,Clinics: PediatricsPTC58-0313 ,Physics: Treatment PlanningPTC58-0659 ,Poster AbstractsClinics: CNSPTC58-0290 ,Physics: Commissioning New FacilitiesPTC58-0064 ,Physics: Adaptive TherapyPTC58-0396 ,Physics: Dose Calculation and OptimisationPTC58-0281 ,Physics: Quality Assurance and VerificationPTC58-0427 ,Physics: Quality Assurance and VerificationPTC58-0669 ,General: New Horizons SessionPTC58-0191 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0217 ,Physics: Quality Assurance and VerificationPTC58-0303 ,Physics: Quality Assurance and VerificationPTC58-0665 ,Clinics: Sarcoma - LymphomaPTC58-0495 ,Physics: Dose Calculation and OptimisationPTC58-0398 ,Physics: Quality Assurance and VerificationPTC58-0667 ,Physics: Quality Assurance and VerificationPTC58-0425 ,Physics: Quality Assurance and VerificationPTC58-0541 ,Physics: Treatment PlanningPTC58-0584 ,Physics: Quality Assurance and VerificationPTC58-0540 ,Biology: Drug and Immunotherapy Combinations Poster Discussion SessionsPTC58-0163 ,Physics: Treatment PlanningPTC58-0224 ,Physics: Treatment PlanningPTC58-0229 ,Clinics: PediatricsPTC58-0249 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0555 ,Clinics: PediatricPTC58-0463 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0556 ,Physics: Absolute and Relative DosimetryPTC58-0498 ,Physics: Commissioning New FacilitiesPTC58-0078 ,Physics: Dose Calculation and OptimisationPTC58-0270 ,Physics: Dose Calculation and OptimisationPTC58-0032 ,Physics: Dose Calculation and OptimisationPTC58-0274 ,Physics: 4D Treatment and DeliveryPTC58-0614 ,Physics: Dose Calculation and OptimisationPTC58-0026 ,Clinics: Head and Neck / EyePTC58-0280 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0091 ,Physics: Treatment PlanningPTC58-0593 ,Biology: Drug and Immunotherapy CombinationsPTC58-0012 ,Physics: Dose Calculation and OptimisationPTC58-0025 ,Physics: Dose Calculation and OptimisationPTC58-0146 ,Clinics: Sarcoma - LymphomaPTC58-0261 ,Physics: Treatment PlanningPTC58-0110 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0733 ,Physics: Quality Assurance and VerificationPTC58-0554 ,Physics: Treatment PlanningPTC58-0597 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0330 ,Physics: Treatment PlanningPTC58-0115 ,Physics: Treatment PlanningPTC58-0598 ,Physics: Absolute and Relative DosimetryPTC58-0040 ,Physics: Absolute and Relative DosimetryPTC58-0282 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0399 ,Physics: Absolute and Relative DosimetryPTC58-0283 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0569 ,Clinics: GUPTC58-0647 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0506 ,Physics: Commissioning New FacilitiesPTC58-0047 ,Physics: Dose Calculation and OptimisationPTC58-0067 ,Clinics: GUPTC58-0409 ,Physics: Dose Calculation and OptimisationPTC58-0065 ,Biology: BNCT Poster Discussion SessionsPTC58-0586 ,Physics: Absolute and Relative Dosimetry PTC58-0393 ,Physics: Image GuidancePTC58-0712 ,Physics: Quality Assurance and VerificationPTC58-0645 ,Physics: Treatment PlanningPTC58-0683 ,Biology: BNCT Poster Discussion SessionsPTC58-0107 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0266 ,Physics: Monitoring and Modelling MotionPTC58-0530 ,Biology: BNCT Poster Discussion SessionsPTC58-0341 ,Physics: Commissioning New FacilitiesPTC58-0172 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0456 ,Physics: Dose Calculation and OptimisationPTC58-0170 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0458 ,Physics: Absolute and Relative DosimetryPTC58-0034 ,Physics: Quality Assurance and VerificationPTC58-0417 ,Physics: Quality Assurance and VerificationPTC58-0413 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0492 ,Physics: Dose Calculation and OptimisationPTC58-0168 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0724 ,Physics: Treatment PlanningPTC58-0694 ,Physics: Adaptive TherapyPTC58-0005 ,Physics: Treatment PlanningPTC58-0696 ,Physics: Treatment PlanningPTC58-0453 ,Physics: Adaptive TherapyPTC58-0366 ,Clinics: BreastPTC58-0197 ,Physics: Beam Delivery and Nozzle DesignPTC58-0652 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0017 ,Physics: Treatment PlanningPTC58-0338 ,Clinics: Head and Neck / EyePTC58-0539 ,General: New Horizons SessionPTC58-0390 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0651 ,General: New HorizonsPTC58-0660 ,Physics: Dose Calculation and OptimisationPTC58-0360 ,Physics: Image GuidancePTC58-0297 ,Physics: 4D Treatment and DeliveryPTC58-0147 ,Scientific: RTTPTC58-0388 ,Physics: Dose Calculation and OptimisationPTC58-0484 ,General: New HorizonsPTC58-0301 ,Physics: Dose Calculation and OptimisationPTC58-0485 ,General: New HorizonsPTC58-0304 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0532 ,Clinics: GIPTC58-0575 ,General: New HorizonsPTC58-0306 ,Physics: Quality Assurance and VerificationPTC58-0589 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0344 ,Physics: Quality Assurance and VerificationPTC58-0225 ,Physics: Treatment PlanningPTC58-0381 ,Physics: Quality Assurance and VerificationPTC58-0467 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0585 ,Physics: Commissioning New FacilitiesPTC58-0416 ,Physics: Quality Assurance and VerificationPTC58-0228 ,Physics: Quality Assurance and VerificationPTC58-0348 ,Physics: Dose Calculation and OptimisationPTC58-0234 ,Physics: Quality Assurance and VerificationPTC58-0101 ,Physics: Treatment PlanningPTC58-0386 ,Physics: Dose Calculation and OptimisationPTC58-0118 ,Physics: Treatment PlanningPTC58-0265 ,Physics: Dose Calculation and OptimisationPTC58-0119 ,Clinics: GIPTC58-0218 ,Physics: Treatment PlanningPTC58-0267 ,Physics: Treatment PlanningPTC58-0387 ,Clinics: BreastPTC58-0142 ,Physics: Treatment PlanningPTC58-0269 ,Physics: Beam Delivery and Nozzle DesignPTC58-0620 ,Clinics: PediatricsPTC58-0048 ,Physics: Quality Assurance and VerificationPTC58-0220 ,Physics: Quality Assurance and VerificationPTC58-0461 ,Physics: Treatment PlanningPTC58-0029 ,Physics: Absolute and Relative DosimetryPTC58-0571 ,Physics: Image GuidancePTC58-0046 ,Clinics: GUPTC58-0557 ,Physics: Absolute and Relative DosimetryPTC58-0211 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0131 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0373 ,General: New HorizonsPTC58-0411 ,Physics: Dose Calculation and OptimisationPTC58-0595 ,Clinics: CNS / Skull BasePTC58-0361 ,General: New HorizonsPTC58-0414 ,General: New HorizonsPTC58-0537 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0628 ,Physics: Treatment PlanningPTC58-0271 ,Physics: Commissioning New FacilitiesPTC58-0307 ,Physics: Quality Assurance and VerificationPTC58-0359 ,Physics: Quality Assurance and VerificationPTC58-0354 ,General: New HorizonsPTC58-0419 ,Physics: Treatment PlanningPTC58-0035 ,Biology: BNCTPTC58-0474 ,Clinics: GIPTC58-0460 ,Biology: BNCTPTC58-0596 ,Clinics: GIPTC58-0222 ,Physics: Image GuidancePTC58-0193 ,Clinics: PediatricPTC58-0312 ,Clinics: GUPTC58-0441 ,Clinics: LungPTC58-0701 ,Clinics: EyePTC58-0536 ,Clinics: GUPTC58-0205 ,Physics: Dose Calculation and OptimisationPTC58-0140 ,Clinics: GUPTC58-0208 ,Physics: Dose Calculation and OptimisationPTC58-0020 ,Physics: Image GuidancePTC58-0195 ,Poster AbstractsClinics: CNSPTC58-0717 ,Physics: Quality Assurance and VerificationPTC58-0325 ,Physics: Dose Calculation and OptimisationPTC58-0015 ,Physics: Commissioning New FacilitiesPTC58-0634 ,General: New HorizonsPTC58-0646 ,Physics: Quality Assurance and VerificationPTC58-0566 ,Physics: Dose Calculation and OptimisationPTC58-0134 ,Physics: Dose Calculation and OptimisationPTC58-0376 ,Biology: Mathematical Modelling SimulationPTC58-0462 ,Biology: BNCTPTC58-0567 ,General: New HorizonsPTC58-0527 ,Physics: Treatment PlanningPTC58-0482 ,Clinics: GI, GU, BreastPTC58-0693 ,Physics: Commissioning New FacilitiesPTC58-0518 ,Physics: Quality Assurance and VerificationPTC58-0686 ,Physics: Quality Assurance and VerificationPTC58-0202 ,Physics: Quality Assurance and VerificationPTC58-0322 ,Physics: Quality Assurance and VerificationPTC58-0564 ,Physics: Quality Assurance and VerificationPTC58-0680 ,Physics: Treatment PlanningPTC58-0247 ,Physics: Quality Assurance and VerificationPTC58-0682 ,Physics: Quality Assurance and VerificationPTC58-0440 ,Biology: Translational and BiomarkersPTC58-0514 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0178 ,Clinics: EyePTC58-0520 ,Physics: Absolute and Relative DosimetryPTC58-0231 ,Clinics: Head and Neck / EyePTC58-0424 ,Physics: Absolute and Relative DosimetryPTC58-0471 ,Physics: Absolute and Relative DosimetryPTC58-0356 ,Physics: Dose Calculation and OptimisationPTC58-0491 ,Physics: Dose Calculation and OptimisationPTC58-0250 ,Physics: Commissioning New FacilitiesPTC58-0650 ,Biology: Biology and Clinical InterfacePTC58-0719 ,Physics: Absolute and Relative DosimetryPTC58-0232 ,Physics: Absolute and Relative DosimetryPTC58-0353 ,General: New HorizonsPTC58-0511 ,Physics: Quality Assurance and VerificationPTC58-0219 ,Physics: Absolute and Relative DosimetryPTC58-0238 ,General: New HorizonsPTC58-0512 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0401 ,Clinics: PediatricPTC58-0688 ,Physics: Quality Assurance and VerificationPTC58-0457 ,Physics: Quality Assurance and VerificationPTC58-0214 ,Physics: Quality Assurance and VerificationPTC58-0459 ,General: New HorizonsPTC58-0516 ,Physics: Treatment PlanningPTC58-0372 ,Physics: Treatment PlanningPTC58-0011 ,Physics: Treatment PlanningPTC58-0254 ,Physics: Quality Assurance and VerificationPTC58-0332 ,Clinics: CNS / Skull BasePTC58-0468 ,Biology: Mathematical Modelling SimulationPTC58-0357 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0649 ,Physics: Dose Calculation and OptimisationPTC58-0006 ,Physics: Quality Assurance and VerificationPTC58-0212 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0565 ,Physics: Treatment PlanningPTC58-0018 ,Physics: Treatment PlanningPTC58-0019 ,Clinics: BreastPTC58-0576 ,Clinics: Head and Neck / EyePTC58-0335 ,Clinics: Head and Neck / EyePTC58-0577 ,General: New HorizonsPTC58-0621 ,Physics: Absolute and Relative DosimetryPTC58-0426 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0268 ,Physics: Absolute and Relative DosimetryPTC58-0423 ,Physics: Treatment PlanningPTC58-0184 ,Physics: Quality Assurance and VerificationPTC58-0149 ,Clinics: GIPTC58-0378 ,Clinics: GIPTC58-0257 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0662 ,General: New HorizonsPTC58-0627 ,Physics: Treatment PlanningPTC58-0186 ,Physics: Treatment PlanningPTC58-0185 ,Physics: Quality Assurance and VerificationPTC58-0144 ,Biology: BNCT Poster Discussion SessionsPTC58-0602 ,Physics: Treatment PlanningPTC58-0189 ,Physics: Dose Calculation and OptimisationPTC58-0315 ,Clinics: Head and neckPTC58-0300 ,General: New Horizons SessionPTC58-0347 ,Physics: Image GuidancePTC58-0082 ,Clinics: BreastPTC58-0443 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0629 ,Physics: Adaptive Therapy Poster Discussion SessionsPTC58-0007 ,Physics: Commissioning New FacilitiesPTC58-0472 ,Clinics: GI, GU, BreastPTC58-0515 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0606 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0450 ,Physics: Absolute and Relative DosimetryPTC58-0657 ,Physics: Dose Calculation and OptimisationPTC58-0551 ,Physics: Treatment PlanningPTC58-0192 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0675 ,Physics: Treatment PlanningPTC58-0194 ,Physics: Dose Calculation and OptimisationPTC58-0544 ,Physics: Treatment PlanningPTC58-0199 ,Physics: Quality Assurance and VerificationPTC58-0037 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0207 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0434 ,Physics: Quality Assurance and VerificationPTC58-0036 ,Physics: Quality Assurance and VerificationPTC58-0278 ,Physics: Quality Assurance and VerificationPTC58-0394 ,Physics: Quality Assurance and VerificationPTC58-0151 ,Physics: Quality Assurance and VerificationPTC58-0154 ,Physics: Dose Calculation and OptimisationPTC58-0428 ,Clinics: BreastPTC58-0116 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0435 ,Physics: Commissioning New FacilitiesPTC58-0681 ,Physics: Absolute and Relative DosimetryPTC58-0323 ,Physics: Dose Calculation and OptimisationPTC58-0583 ,Physics: Absolute and Relative DosimetryPTC58-0448 ,Clinics: CNS / Skull BasePTC58-0251 ,General: New HorizonsPTC58-0721 ,Physics: Absolute and Relative DosimetryPTC58-0203 ,Physics: Dose Calculation and OptimisationPTC58-0455 ,Physics: 4D Treatment and DeliveryPTC58-0130 ,Physics: Commissioning New FacilitiesPTC58-0679 ,Physics: Absolute and Relative DosimetryPTC58-0329 ,General: New HorizonsPTC58-0604 ,Physics: Absolute and Relative DosimetryPTC58-0449 ,Clinics: CNS / Skull BasePTC58-0132 ,General: New HorizonsPTC58-0607 ,Physics: Quality Assurance and VerificationPTC58-0122 ,Physics: Quality Assurance and VerificationPTC58-0243 ,Physics: Treatment PlanningPTC58-0165 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0437 ,Physics: 4D Treatment and DeliveryPTC58-0377 ,Physics: Quality Assurance and VerificationPTC58-0125 ,Physics: Quality Assurance and VerificationPTC58-0245 ,Physics: Dose Calculation and OptimisationPTC58-0337 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0334 ,Physics: Quality Assurance and VerificationPTC58-0121 ,General: New Horizons SessionPTC58-0563 ,General: New Horizons SessionPTC58-0321 ,Clinics: Head and Neck / EyePTC58-0477 ,Physics: Quality Assurance and VerificationPTC58-0480 ,Clinics: GUPTC58-0010 ,Clinics: EyePTC58-0684 ,Clinics: GUPTC58-0496 ,Clinics: Head and neckPTC58-0676 ,Clinics: GUPTC58-0137 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0256 ,Physics: 4D Treatment and DeliveryPTC58-0117 ,Physics: Absolute and Relative DosimetryPTC58-0552 ,Physics: Absolute and Relative DosimetryPTC58-0310 ,Physics: Absolute and Relative DosimetryPTC58-0672 ,Physics: Absolute and Relative DosimetryPTC58-0436 ,Physics: Dose Calculation and OptimisationPTC58-0452 ,Physics: Dose Calculation and OptimisationPTC58-0331 ,Physics: Commissioning New FacilitiesPTC58-0213 ,Biology: Mathematical Modelling SimulationPTC58-0272 ,Clinics: EyePTC58-0326 ,Physics: Commissioning New FacilitiesPTC58-0568 ,Physics: Dose Calculation and OptimisationPTC58-0444 ,Physics: Quality Assurance and VerificationPTC58-0379 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0095 ,Physics: Treatment PlanningPTC58-0053 ,Physics: Absolute and Relative DosimetryPTC58-0438 ,Physics: Absolute and Relative DosimetryPTC58-0317 ,Physics: Quality Assurance and VerificationPTC58-0497 ,Physics: Quality Assurance and VerificationPTC58-0375 ,Physics: Treatment PlanningPTC58-0056 ,Physics: 4D Treatment and DeliveryPTC58-0124 ,Clinics: GIPTC58-0009 ,Physics: Quality Assurance and VerificationPTC58-0014 ,Physics: Quality Assurance and VerificationPTC58-0374 ,Clinics: LungPTC58-0727 ,General: New Horizons SessionPTC58-0578 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0470 ,Clinics: LungPTC58-0204 ,Clinics: Head and neckPTC58-0227 ,Clinics: LungPTC58-0446 ,Physics: Quality Assurance and VerificationPTC58-0190 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0609 ,Clinics: LungPTC58-0689 ,General: New HorizonsPTC58-0021 ,General: New HorizonsPTC58-0262 ,Biology: BNCT Poster Discussion SessionsPTC58-0081 ,Clinics: GIPTC58-0726 ,General: New HorizonsPTC58-0145 ,Physics: Image GuidancePTC58-0573 ,General: New HorizonsPTC58-0027 ,General: New HorizonsPTC58-0028 ,Biology: Mathematical Modelling and SimulationPTC58-0148 ,Physics: Dose Calculation and OptimisationPTC58-0635 ,Physics: Image GuidancePTC58-0215 ,Physics: Image GuidancePTC58-0336 ,Poster AbstractsClinics: CNSPTC58-0535 ,Physics: Quality Assurance and VerificationPTC58-0187 ,Biology: BNCT Poster Discussion SessionsPTC58-0084 ,General: New Investigator SessionPTC58-0339 ,General: New Horizons SessionPTC58-0420 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0523 ,Biology: BNCT Poster Discussion SessionsPTC58-0088 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0112 ,Physics: Quality Assurance and VerificationPTC58-0182 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0615 ,Physics: Quality Assurance and VerificationPTC58-0080 ,Biology: BNCTPTC58-0085 ,Physics: Adaptive Therapy Poster Discussion SessionsPTC58-0722 ,General: New HorizonsPTC58-0253 ,General: New HorizonsPTC58-0255 ,Clinics: PediatricPTC58-0703 ,General: New HorizonsPTC58-0499 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0380 ,General: New HorizonsPTC58-0259 ,Clinics: GI, GU, BreastPTC58-0288 ,Clinics: GI, GU, BreastPTC58-0045 ,Physics: Absolute and Relative DosimetryPTC58-0619 ,Clinics: PediatricPTC58-0707 ,Physics: Quality Assurance and VerificationPTC58-0196 ,Physics: Quality Assurance and VerificationPTC58-0074 ,Physics: Quality Assurance and VerificationPTC58-0077 ,Biology: BNCT Poster Discussion SessionsPTC58-0073 ,Biology: BNCTPTC58-0075 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0093 ,Clinics: GUPTC58-0161 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0371 ,Physics: Monitoring and Modelling MotionPTC58-0181 ,General: New HorizonsPTC58-0120 ,General: New HorizonsPTC58-0362 ,General: New HorizonsPTC58-0364 ,Physics: Image GuidancePTC58-0473 ,Scientific: RTTPTC58-0641 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0296 ,General: New HorizonsPTC58-0004 ,General: New HorizonsPTC58-0128 ,Clinics: BreastPTC58-0316 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0236 ,General: New HorizonsPTC58-0008 ,General: New Investigator SessionPTC58-0673 ,Physics: Quality Assurance and VerificationPTC58-0167 ,Physics: Quality Assurance and VerificationPTC58-0289 ,Physics: Quality Assurance and VerificationPTC58-0284 ,General: New Horizons SessionPTC58-0522 ,Physics: Quality Assurance and VerificationPTC58-0164 ,Physics: Quality Assurance and VerificationPTC58-0285 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0623 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0502 ,Clinics: GUPTC58-0293 ,Biology: Translational and BiomarkersPTC58-0599 ,Biology: BNCTPTC58-0063 ,Clinics: LungPTC58-0656 ,General: New HorizonsPTC58-0592 ,Biology: BNCT Poster Discussion SessionsPTC58-0092 ,Poster AbstractsClinics: CNSPTC58-0302 ,Physics: Image GuidancePTC58-0464 ,General: New HorizonsPTC58-0352 ,Physics: Image GuidancePTC58-0465 ,General: New HorizonsPTC58-0476 ,Physics: Image GuidancePTC58-0100 ,General: New HorizonsPTC58-0235 ,Biology: Mathematical Modelling and SimulationPTC58-0349 ,Physics: Treatment PlanningPTC58-0094 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0367 ,Physics: Dose Calculation and OptimisationPTC58-0400 ,Biology: Translational and BiomarkersPTC58-0244 ,Physics: Dose Calculation and OptimisationPTC58-0640 ,Biology: Mathematical Modelling and SimulationPTC58-0355 ,General: New Investigator SessionPTC58-0320 ,Physics: Quality Assurance and VerificationPTC58-0057 ,Physics: Quality Assurance and VerificationPTC58-0174 ,Physics: Quality Assurance and VerificationPTC58-0295 ,Physics: Dose Calculation and OptimisationPTC58-0529 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0123 ,Physics: Quality Assurance and VerificationPTC58-0171 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0049 ,Clinics: BreastPTC58-0731 ,General: New HorizonsPTC58-0223 ,General: New HorizonsPTC58-0102 ,General: New HorizonsPTC58-0466 ,Scientific: RTTPTC58-0503 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0389 ,General: New HorizonsPTC58-0108 ,General: New HorizonsPTC58-0109 ,Physics: Commissioning New FacilitiesPTC58-0736 ,Biology: Mathematical Modelling and SimulationPTC58-0343 ,Biology: Mathematical Modelling and SimulationPTC58-0342 ,Clinics: GI, GU, BreastPTC58-0237 ,Physics: Dose Calculation and OptimisationPTC58-0711 ,Biology: Mathematical Modelling and SimulationPTC58-0581 ,Clinics: GI, GU, BreastPTC58-0114 ,Clinics: Base of SkullPTC58-0730 ,Clinics: Head and neckPTC58-0383 ,Clinics: CNS / Skull BasePTC58-0559 ,Clinics: Base of SkullPTC58-0613 ,General: New HorizonsPTC58-0691 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0054 ,General: New HorizonsPTC58-0210 ,Clinics: BreastPTC58-0729 ,General: New HorizonsPTC58-0574 ,Clinics: GI, GU, BreastPTC58-0239 ,Scientific: RTTPTC58-0637 ,General: New HorizonsPTC58-0579 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0176 ,General: New HorizonsPTC58-0699 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0156 ,Biology: Mathematical Modelling and SimulationPTC58-0333 ,Biology: Translational and BiomarkersPTC58-0345 ,Physics: Image GuidancePTC58-0369 ,Physics: Commissioning New FacilitiesPTC58-0509 ,Biology: Mathematical Modelling SimulationPTC58-0658 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0051 ,General: New Investigator SessionPTC58-0548 ,Clinics: GI, GU, BreastPTC58-0241 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0412 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0024 ,Clinics: LungPTC58-0226 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0069 ,General: New HorizonsPTC58-0562 ,General: New HorizonsPTC58-0561 ,General: New HorizonsPTC58-0201 ,Biology: Mathematical Modelling and SimulationPTC58-0439 ,General: New HorizonsPTC58-0445 ,General: New HorizonsPTC58-0324 ,Physics: Image GuidancePTC58-0031 ,Biology: Mathematical Modelling and SimulationPTC58-0558 ,Physics: Image GuidancePTC58-0392 ,Biology: Mathematical Modelling and SimulationPTC58-0678 ,Physics: Beam Delivery and Nozzle DesignPTC58-0090 ,General: New Investigator SessionPTC58-0630 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0524 ,Physics: Commissioning New FacilitiesPTC58-0713 ,Clinics: GI, GU, BreastPTC58-0139 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0248 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0368 ,Biology: Enhanced Biology in Treatment PlanningPTC58-0519 ,General: New Horizons SessionPTC58-0720 ,Physics: Quality Assurance and VerificationPTC58-0083 ,General: New HorizonsPTC58-0311 ,General: New HorizonsPTC58-0674 ,General: New HorizonsPTC58-0553 ,Physics: Image GuidancePTC58-0023 ,Scientific: RTTPTC58-0612 ,General: New HorizonsPTC58-0677 ,Biology: Mathematical Modelling and SimulationPTC58-0545 ,Physics: Dose Calculation and OptimisationPTC58-0601 ,Physics: Dose Calculation and OptimisationPTC58-0725 ,Physics: Quality Assurance and VerificationPTC58-0098 ,Physics: Dose Calculation and OptimisationPTC58-0605 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0517 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0618 ,Physics: Monitoring and Modelling MotionPTC58-0481 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0071 ,Physics: Adaptive TherapyPTC58-0351 ,Physics: 4D Treatment and DeliveryPTC58-0702 ,Physics: Image GuidancePTC58-0734 ,Physics: Image GuidancePTC58-0611 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0486 ,Physics: Absolute and Relative Dosimetry Poster Discussion SessionsPTC58-0442 ,Biology: Drug and Immunotherapy CombinationsPTC58-0327 ,Clinics: Head and Neck / EyePTC58-0096 ,Clinics: LungPTC58-0159 ,Physics: Treatment PlanningPTC58-0708 ,General: New HorizonsPTC58-0097 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0350 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0016 ,Physics: Adaptive TherapyPTC58-0104 ,Physics: Absolute and Relative Dosimetry Poster Discussion SessionsPTC58-0433 ,Physics: Image GuidancePTC58-0608 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0610 ,Clinics: Head and neckPTC58-0058 ,Physics: Treatment PlanningPTC58-0715 ,Clinics: Head and neckPTC58-0298 ,Clinics: EyePTC58-0099 ,General: New HorizonsPTC58-0086 ,General: New HorizonsPTC58-0089 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0200 ,Poster AbstractsClinics: CNSPTC58-0157 ,Clinics: LungPTC58-0141 ,Clinics: LungPTC58-0260 ,Clinics: LungPTC58-0264 ,Physics: Image GuidancePTC58-0513 ,Physics: Image GuidancePTC58-0631 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0469 ,Biology: BNCT Poster Discussion SessionsPTC58-0384 ,Physics: Image GuidancePTC58-0639 ,Clinics: PediatricsPTC58-0700 ,Clinics: LungPTC58-0136 ,Clinics: BreastPTC58-0706 ,General: New HorizonsPTC58-0079 ,Biology: Drug and Immunotherapy Combinations Poster Discussion SessionsPTC58-0406 ,Clinics: Base of SkullPTC58-0382 ,Physics: Image GuidancePTC58-0624 ,Physics: Beam Delivery and Nozzle DesignPTC58-0173 ,Biology: Drug and Immunotherapy CombinationsPTC58-0358 ,Poster AbstractsClinics: CNSPTC58-0690 ,General: New HorizonsPTC58-0061 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0580 ,Physics: Monitoring and Modelling MotionPTC58-0162 ,Physics: Adaptive TherapyPTC58-0550 ,Physics: Adaptive TherapyPTC58-0430 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0103 ,General: New Investigator SessionPTC58-0252 ,Physics: Quality Assurance and VerificationPTC58-0704 ,Physics: Image GuidancePTC58-0418 ,Clinics: Base of SkullPTC58-0572 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0106 ,Physics: Beam Delivery and Nozzle DesignPTC58-0022 ,Physics: Monitoring and Modelling MotionPTC58-0279 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0447 ,Physics: Treatment PlanningPTC58-0622 ,Clinics: PediatricsPTC58-0644 ,Biology: Biology and Clinical InterfacePTC58-0490 ,Clinics: CNS / Skull BasePTC58-0716 ,General: New HorizonsPTC58-0292 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0570 ,General: New HorizonsPTC58-0059 ,Physics: Quality Assurance and VerificationPTC58-0710 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0216 ,Physics: Image GuidancePTC58-0404 ,Physics: Image GuidancePTC58-0525 ,Physics: Image GuidancePTC58-0526 ,Poster AbstractsClinics: CNSPTC58-0328 ,Clinics: LungPTC58-0070 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0135 ,Biology: BNCT Poster Discussion SessionsPTC58-0391 ,Physics: Treatment PlanningPTC58-0510 ,Physics: Treatment PlanningPTC58-0636 ,Physics: Treatment PlanningPTC58-0638 ,Physics: Image GuidancePTC58-0408 ,Physics: Absolute and Relative Dosimetry Poster Discussion SessionsPTC58-0632 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0318 ,Biology: Enhanced Biology in Treatment PlanningPTC58-0246 ,Clinics: PediatricsPTC58-0504 ,General: New HorizonsPTC58-0160 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0076 ,Physics: Monitoring and Modelling MotionPTC58-0143 ,Biology: Mathematical Modelling and SimulationPTC58-0718 ,Physics: Image GuidancePTC58-0671 ,Clinics: LungPTC58-0183 ,Physics: Image GuidancePTC58-0670 ,Report ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0422 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0129 ,Physics: Adaptive Therapy Poster Discussion SessionsPTC58-0705 ,Biology: Enhanced Biology in Treatment PlanningPTC58-0258 ,General: New HorizonsPTC58-0030 ,General: New HorizonsPTC58-0150 ,Biology: Biology and Clinical InterfacePTC58-0479 ,General: New HorizonsPTC58-0153 ,Clinics: PediatricPTC58-0087 ,General: New HorizonsPTC58-0152 ,General: New HorizonsPTC58-0155 ,General: New HorizonsPTC58-0033 ,General: New HorizonsPTC58-0158 ,Physics: Image GuidancePTC58-0429 ,Biology: Translational and BiomarkersPTC58-0287 ,Physics: Adaptive TherapyPTC58-0403 ,Physics: Image GuidancePTC58-0309 - Published
- 2020
3. Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit
- Author
-
Lee, K C, Hamstra, D A, Bullarayasamudram, S, Bhojani, M S, Moffat, B A, Dornfeld, K J, Ross, B D, and Rehemtulla, A
- Published
- 2006
- Full Text
- View/download PDF
4. Counseling patients about sexual health when considering post-prostatectomy radiation treatment
- Author
-
Wittmann, D, Montie, J E, Hamstra, D A, Sandler, H, and Wood, D P, Jr
- Published
- 2009
5. Defining a standard set of patient-centered outcomes for men with localized prostate cancer
- Author
-
Martin, N.E. (Neil E.), Massey, L. (Laura), Stowell, C. (Caleb), Bangma, C.H. (Chris), Briganti, A. (Alberto), Bill-Axelson, A. (Anna), Blute, M. (Michael), Catto, J.W.F. (James), Chen, R.C. (Ronald C.), D'Amico, A.V. (Anthony V.), Feick, G. (Günter), Fitzpatrick, J.M. (John), Frank, S.J. (Steven J.), Froehner, M. (Michael), Frydenberg, M. (Mark), Glaser, A. (Adam), Graefen, M. (Markus), Hamstra, D. (Daniel), Kibel, A. (Adam), Mendenhall, N. (Nancy), Moretti, K. (Kim), Ramon, J. (Jacob), Roos, I. (Ian), Sandler, H. (Howard), Sullivan, F.J. (Francis J.), Swanson, D. (David), Tewari, A. (Ashutosh), Vickers, A.J. (Andrew), Wiegel, T. (Thomas), Huland, H. (Hartwig), Martin, N.E. (Neil E.), Massey, L. (Laura), Stowell, C. (Caleb), Bangma, C.H. (Chris), Briganti, A. (Alberto), Bill-Axelson, A. (Anna), Blute, M. (Michael), Catto, J.W.F. (James), Chen, R.C. (Ronald C.), D'Amico, A.V. (Anthony V.), Feick, G. (Günter), Fitzpatrick, J.M. (John), Frank, S.J. (Steven J.), Froehner, M. (Michael), Frydenberg, M. (Mark), Glaser, A. (Adam), Graefen, M. (Markus), Hamstra, D. (Daniel), Kibel, A. (Adam), Mendenhall, N. (Nancy), Moretti, K. (Kim), Ramon, J. (Jacob), Roos, I. (Ian), Sandler, H. (Howard), Sullivan, F.J. (Francis J.), Swanson, D. (David), Tewari, A. (Ashutosh), Vickers, A.J. (Andrew), Wiegel, T. (Thomas), and Huland, H. (Hartwig)
- Abstract
Background Value-based health care has been proposed as a unifying force to drive improved outcomes and cost containment. Objective To develop a standard set of multidimensional patient-centered health outcomes for tracking, comparing, and improving localized prostate cancer (PCa) treatment value. Design, setting, and participants We convened an international working group of patients, registry experts, urologists, and radiation oncologists to review existing data and practices. Outcome measurements and statistical analysis The group defined a recommended standard set representing who should be tracked, what should be measured and at what time points, and what data are necessary to make meaningful comparisons. Using a modified Delphi method over a series of teleconferences, the group reached consensus for the Standard Set. Results and limitations We recommend that the Standard Set apply to men with newly diagnosed localized PCa treated with active surveillance, surgery, radiation, or other methods. The Standard Set includes acute toxicities occurring within 6 mo of treatment as well as patient-reported outcomes tracked regularly out to 10 yr. Patient-reported domains of urinary incontinence and irritation, bowel symptoms, sexual symptoms, and hormonal symptoms are included, and the recommended measurement tool is the Expanded Prostate Cancer Index Composite Short Form. Disease control outcomes include overall, cause-specific, metastasis-free, and biochemical relapse-free survival. Baseline clinical, pathologic, and comorbidity information is included to improve the interpretability of comparisons. Conclusions We have defined a simple, easily implemented set of outcomes that we believe should be measured in all men with localized PCa as a crucial first step in improving the value of care. Patient summary Measuring, reporting, and comparing identical outcomes across treatments and treatment centers will provide patients and providers with information to make informed
- Published
- 2015
- Full Text
- View/download PDF
6. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer
- Author
-
Martin, N E, Massey, L, Stowell, C, Bangma, C.H., Briganti, A, Bill-Axelson, A, Blute, M, Catto, J, Chen, R C, D'Amico, AV, Feick, G, Fitzpatrick, JM, Frank, S J, Froehner, M, Frydenberg, M, Glaser, A, Graefen, M, Hamstra, D, Kibel, A, Mendenhall, N, Moretti, K, Ramon, J, Roos, I, Sandler, H, Sullivan, F J, Swanson, D, Tewari, A, Vickers, A, Wiegel, T, Huland, H, Martin, N E, Massey, L, Stowell, C, Bangma, C.H., Briganti, A, Bill-Axelson, A, Blute, M, Catto, J, Chen, R C, D'Amico, AV, Feick, G, Fitzpatrick, JM, Frank, S J, Froehner, M, Frydenberg, M, Glaser, A, Graefen, M, Hamstra, D, Kibel, A, Mendenhall, N, Moretti, K, Ramon, J, Roos, I, Sandler, H, Sullivan, F J, Swanson, D, Tewari, A, Vickers, A, Wiegel, T, and Huland, H
- Published
- 2015
7. SU‐E‐T‐530: Knowledge‐Based Treatment Planning and Its Potential Role in the Transition Between Treatment Planning Systems
- Author
-
Masi, K, primary, Archer, P, additional, Hamstra, D, additional, and Matuszak, M, additional
- Published
- 2015
- Full Text
- View/download PDF
8. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer
- Author
-
Zhao, S G, primary, Jackson, W C, additional, Kothari, V, additional, Schipper, M J, additional, Erho, N, additional, Evans, J R, additional, Speers, C, additional, Hamstra, D A, additional, Niknafs, Y S, additional, Nguyen, P L, additional, Schaeffer, E M, additional, Ross, A E, additional, Den, R B, additional, Klein, E A, additional, Jenkins, R B, additional, Davicioni, E, additional, and Feng, F Y, additional
- Published
- 2015
- Full Text
- View/download PDF
9. Is the Fear of Postprostatectomy Radiation Therapy Justified?: An Analysis of Patient-Reported Quality of Life Following Adjuvant or Salvage Radiation
- Author
-
Shumway, D., primary, Daignault, S., additional, Feng, F., additional, Jackson, W., additional, Johnson, S., additional, Miller, D., additional, Wei, J., additional, and Hamstra, D., additional
- Published
- 2014
- Full Text
- View/download PDF
10. Patient-Reported Outcomes for Quality of Life (QOL) by Expanded Prostate Cancer Index (EPIC) 15 Years Posttreatment
- Author
-
Zhou, J., primary, Daignault-Newton, S., additional, Miller, D., additional, Wei, J., additional, Dunn, R., additional, Johnson, S., additional, Jackson, W., additional, Imam, H., additional, Kazzi, N., additional, McLaughlin, P., additional, Sandler, H., additional, Sanda, M., additional, and Hamstra, D., additional
- Published
- 2014
- Full Text
- View/download PDF
11. RE: Mortality After Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer
- Author
-
Hamstra, D. A., primary and Chen, R. C., additional
- Published
- 2014
- Full Text
- View/download PDF
12. Concurrent whole brain radiotherapy and bortezomib for brain metastasis
- Author
-
Lao, CD, Friedman, J, Tsien, CI, Normolle, DP, Chapman, C, Cao, Y, Lee, O, Schipper, M, Van Poznak, C, Hamstra, D, Lawrence, T, Hayman, J, Redman, BG, Lao, CD, Friedman, J, Tsien, CI, Normolle, DP, Chapman, C, Cao, Y, Lee, O, Schipper, M, Van Poznak, C, Hamstra, D, Lawrence, T, Hayman, J, and Redman, BG
- Abstract
Background: Survival of patients with brain metastasis particularly from historically more radio-resistant malignancies remains dismal. A phase I study of concurrent bortezomib and whole brain radiotherapy was conducted to determine the tolerance and safety of this approach in patients with previously untreated brain metastasis.Methods: A phase I dose escalation study evaluated the safety of bortezomib (0.9, 1.1, 1.3, 1.5, and 1.7 mg/m2) given on days 1, 4, 8 and 11 of whole brain radiotherapy. Patients with confirmed brain metastasis were recruited for participation. The primary endpoint was the dose-limiting toxicity, defined as any ≥ grade 3 non-hematologic toxicity or grade ≥ 4 hematologic toxicity from the start of treatment to one month post irradiation. Time-to-Event Continual Reassessment Method (TITE-CRM) was used to determine dose escalation. A companion study of brain diffusion tensor imaging MRI was conducted on a subset of patients to assess changes in the brain that might predict delayed cognitive effects.Results: Twenty-four patients were recruited and completed the planned therapy. Patients with melanoma accounted for 83% of all participants. The bortezomib dose was escalated as planned to the highest dose of 1.7 mg/m2/dose. No grade 4/5 toxicities related to treatment were observed. Two patients had grade 3 dose-limiting toxicities (hyponatremia and encephalopathy). A partial or minor response was observed in 38% of patients. Bortezomib showed greater demyelination in hippocampus-associated white matter structures on MRI one month after radiotherapy compared to patients not treated with bortezomib (increase in radial diffusivity +16.8% versus 4.8%; p = 0.0023).Conclusions: Concurrent bortezomib and whole brain irradiation for brain metastasis is well tolerated at one month follow-up, but MRI changes that have been shown to predict delayed cognitive function can be detected within one month of treatment. © 2013 Lao et al.; licensee BioMed Central Ltd
- Published
- 2013
13. De invloed van sekse en manier van lesgeven van de docent op de attitudeverandering in relationeel geweld na het preventieprogramma “ Stay in Love” - Levert de sekse van de docent en de manier van lesgeven een verschil op in de attitudeverandering van relationeel geweld?
- Author
-
Hamstra, D., Pelt, R.D. van (Thesis Advisor), Kempes, M.M., Hamstra, D., Pelt, R.D. van (Thesis Advisor), and Kempes, M.M.
- Published
- 2010
14. PEDIATRICS CLINICAL RESEARCH
- Author
-
Antony, R., primary, Zagardo, M., additional, Gujrati, M., additional, Lin, J., additional, Antony, R., additional, Al-Rahawan, M., additional, Broniscer, A., additional, Bhardwaj, R., additional, Hampton, C., additional, Ozols, V., additional, Chakravadhanula, M., additional, Bouffet, E., additional, Hawkins, C., additional, Scheinemann, K., additional, Zelcer, S., additional, Johnston, D., additional, Lafay-Cousin, L., additional, Larouche, V., additional, Jabado, N., additional, Carret, A. S., additional, Hukin, J., additional, Eisenstat, D., additional, Pond, G., additional, Poskitt, K., additional, Wilson, B., additional, Bartels, U., additional, Tabori, U., additional, Dhall, G., additional, Haley, K., additional, Finlay, J., additional, Rushing, T., additional, Sposto, R., additional, Seeger, R., additional, Garvin, J., additional, Rupani, K., additional, Stark, E., additional, Anderson, R., additional, Feldstein, N., additional, Grill, J., additional, Hargrave, D., additional, Massimino, M., additional, Jaspan, T., additional, Varlet, P., additional, Jones, C., additional, Morgan, P., additional, Le Deley, M. C., additional, Azizi, A., additional, Canete, A., additional, Saran, F., additional, Bachir, J., additional, Bubuteishvili-Pacaud, L., additional, Rousseau, R., additional, Vassal, G., additional, Gupta, S., additional, Robinson, N., additional, Dhir, N., additional, Wong, K., additional, Zhou, S., additional, Kumabe, T., additional, Kawaguchi, T., additional, Saito, R., additional, Kanamori, M., additional, Yamashita, Y., additional, Sonoda, Y., additional, Tominaga, T., additional, Miyagawa, T., additional, Nwachukwu, C., additional, Youland, R., additional, Laack, N., additional, Filipek, I., additional, Drogosiewicz, M., additional, Polnik, M. P.-, additional, Swieszkowska, E., additional, Dembowska-Baginska, B., additional, Jurkiewicz, E., additional, Perek, D., additional, Grajkowska, W., additional, Roszkowski, M., additional, Sobol, G., additional, Musiol, K., additional, Wachowiak, J., additional, Kazmierczak, B., additional, Pogorzelski, J. P. -, additional, Mlynarski, W., additional, Szewczyk, B. Z.-, additional, Wysocki, M., additional, Niedzielska, E., additional, Kowalczyk, J., additional, Slusarz, H. W. -, additional, Balwierz, W., additional, Czepko, E. Z. -, additional, Szolkiewicz, A., additional, Perek-Polnik, M., additional, Lastowska, M., additional, Chojnacka, M., additional, Tarasinska, M., additional, Perreault, S., additional, Chao, K., additional, Ramaswamy, V., additional, Shih, D., additional, Remke, M., additional, Luu, B., additional, Schubert, S., additional, Fisher, P., additional, Partap, S., additional, Vogel, H., additional, Taylor, M., additional, Goumnerova, L., additional, Cho, Y.-J., additional, Robison, N., additional, Brown, R., additional, Cloughesy, T., additional, Davidson, T. B., additional, Krieger, M., additional, Berger, M., additional, Perry, A., additional, Gilles, F., additional, Finlay, J. L., additional, Khemani, J., additional, Britt, B., additional, Grimm, J., additional, Ruge, M. I., additional, Blau, T., additional, Hafkemeyer, V., additional, Hamisch, C., additional, Klinger, K., additional, Simon, T., additional, Sadighi, Z., additional, Ellezam, B., additional, Guindani, M., additional, Ater, J., additional, Shimizu, Y., additional, Arai, H., additional, Miyajima, M., additional, Shimoji, K., additional, Kondo, A., additional, Shinohara, E., additional, Perkins, S., additional, DeWees, T., additional, Slavc, I., additional, Chocholous, M., additional, Leiss, U., additional, Haberler, C., additional, Peyrl, A., additional, Azizi, A. A., additional, Dieckmann, K., additional, Woehrer, A., additional, Dorfer, C., additional, Czech, T., additional, Spence, T., additional, Picard, D., additional, Barszczyk, M., additional, Kim, S.-K., additional, Ra, Y.-S., additional, Fangusaro, J., additional, Toledano, H., additional, Nakamura, H., additional, Fan, X., additional, Muraszko, K. M., additional, Ng, H.-K., additional, Halliday, W., additional, Shago, M., additional, Hawkins, C. E., additional, Huang, A., additional, Suzuki, M., additional, van Zanten, S. V., additional, Jansen, M., additional, van Vuurden, D., additional, Hulleman, E., additional, Idema, S., additional, Noske, D., additional, Wolf, N., additional, Hendrikse, H., additional, Vandertop, P., additional, Kaspers, G. J., additional, Muller, K., additional, Schlamann, A., additional, Warmuth-Metz, M., additional, Pietsch, T., additional, Pietschmann, S., additional, Kortmann, R.-D., additional, Kramm, C. M., additional, von Bueren, A. O., additional, Walston, S., additional, Williams, T., additional, Hamstra, D., additional, Oh, K., additional, Pelloski, C., additional, Zhukova, N., additional, Pole, J., additional, Mistry, M., additional, Fried, I., additional, Lapperiere, N., additional, Dirks, P., additional, An, J., additional, Alon, N., additional, Nathan, P., additional, Greenberg, M., additional, and Malkin, D., additional
- Published
- 2013
- Full Text
- View/download PDF
15. Assessment of Bone Growth Effects Among Medulloblastoma (MB) Patients Treated With Electron Versus Photon Spinal Irradiation
- Author
-
Kapadia, N.S., primary, Oh, K., additional, Hung, J., additional, and Hamstra, D., additional
- Published
- 2012
- Full Text
- View/download PDF
16. Perineural Invasion Predicts for Increased Recurrence, Metastasis, and Death from Prostate Cancer following Treatment with Dose-Escalated Radiation Therapy
- Author
-
Kapadia, N.S., primary, Qian, Y., additional, Stenmark, M.H., additional, Halverson, S., additional, Blas, K., additional, Vance, S., additional, Sandler, H., additional, Hamstra, D., additional, and Feng, F., additional
- Published
- 2011
- Full Text
- View/download PDF
17. TU-G-BRC-04: The Dosimetric Impact of Prostate Rotations during Electromagnetically Guided External Beam Radiation Therapy
- Author
-
Amro, H, primary, Hadley, S, additional, McShan, D, additional, Hamstra, D, additional, Sandler, H, additional, Vineberg, K, additional, and Litzenberg, D, additional
- Published
- 2011
- Full Text
- View/download PDF
18. The interval to biochemical failure versus biochemical failure as predictors for cause specific and overall survival following dose-escalated external beam radiation therapy for prostate cancer.
- Author
-
Kapadia, N. S., primary, Feng, F. Y., additional, Olson, K. B., additional, Sandler, H. M., additional, and Hamstra, D. A., additional
- Published
- 2011
- Full Text
- View/download PDF
19. PARP inhibition reverses radiation resistance conferred by ETS fusions in prostate cancer.
- Author
-
Feng, F. Y., primary, Han, S., additional, Brenner, C., additional, Sabolch, A., additional, Hamstra, D. A., additional, Lawrence, T. S., additional, and Chinnaiyan, A., additional
- Published
- 2011
- Full Text
- View/download PDF
20. Using Gleason pattern 5 to refine risk stratification for prostate cancer patients treated with dose-escalated radiotherapy and androgen-deprivation therapy.
- Author
-
Sabolch, A., primary, Feng, F. Y., additional, Daignault-Newton, S., additional, Halverson, S., additional, Blas, K., additional, Phelps, L., additional, Olson, K. B., additional, Sandler, H. M., additional, and Hamstra, D. A., additional
- Published
- 2011
- Full Text
- View/download PDF
21. Use of percent positive biopsy cores to predict prostate cancer–specific death in patients treated with dose-escalated radiotherapy.
- Author
-
Qian, Y., primary, Feng, F. Y., additional, Halverson, S., additional, Blas, K., additional, Sandler, H. M., additional, and Hamstra, D. A., additional
- Published
- 2011
- Full Text
- View/download PDF
22. Hormonal manipulation of prostate cancer with sequential androgen blockade.
- Author
-
Olson, K. B., primary, Daignault, S., additional, Hamstra, D. A., additional, and Pienta, K. J., additional
- Published
- 2010
- Full Text
- View/download PDF
23. Serum PDGF Decreases during Combined Radiation and Androgen Deprivation Therapy for Prostate Cancer
- Author
-
Contessa, J.N., primary, Wang, G., additional, Pienta, K., additional, Chinnaiyan, A., additional, Wei, J., additional, Hamstra, D., additional, and Sandler, H., additional
- Published
- 2009
- Full Text
- View/download PDF
24. Parametric Response Map Analysis as an Imaging Biomarker for Distinguishing Progression from Pseudo-progression in High Grade Gliomas
- Author
-
Tsien, C., primary, Galban, C.J., additional, Chenevert, T.L., additional, Hamstra, D., additional, Gomez-Hassan, D., additional, Junck, L., additional, Rogers, L., additional, Meyer, C.R., additional, Rehemtulla, A., additional, and Ross, B.D., additional
- Published
- 2008
- Full Text
- View/download PDF
25. The impact of FLIPI on outcome of frontline treatment with single-agent I-131 tositumomab for follicular lymphoma (FL)
- Author
-
Kaminski, M. S., primary, Hamstra, D., additional, Estes, J., additional, and Wahl, R., additional
- Published
- 2006
- Full Text
- View/download PDF
26. Assessment of the functional diffusion map (fDM) as an imaging biomarker for early stratification of glioma clinical response
- Author
-
Ross, B. D., primary, Hamstra, D. A., additional, Chenevert, T. L., additional, Moffat, B. A., additional, Johnson, T. D., additional, Tsein, C., additional, Meyer, C. R., additional, Mukherji, S., additional, Junck, L., additional, Rehemtulla, A., additional, and Lawrence, T. S., additional
- Published
- 2006
- Full Text
- View/download PDF
27. Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit
- Author
-
Lee, K C, primary, Hamstra, D A, additional, Bullarayasamudram, S, additional, Bhojani, M S, additional, Moffat, B A, additional, Dornfeld, K J, additional, Ross, B D, additional, and Rehemtulla, A, additional
- Published
- 2005
- Full Text
- View/download PDF
28. Cause-specific survival is high following radiotherapy or surgery for Gleason score 8–10 prostate cancer
- Author
-
HAMSTRA, D, primary, DUNN, R, additional, WEI, J, additional, MONTIE, J, additional, SANDA, M, additional, and SANDLER, H, additional
- Published
- 2004
- Full Text
- View/download PDF
29. Carboxy-terminal conversion of profibrillin to fibrillin at a basic site by PACE/furin-like activity required for incorporation in the matrix
- Author
-
Raghunath, M., primary, Putnam, E.A., additional, Ritty, T., additional, Hamstra, D., additional, Park, E.S., additional, Tschodrich-Rotter, M., additional, Peters, R., additional, Rehemtulla, A., additional, and Milewicz, D.M., additional
- Published
- 1999
- Full Text
- View/download PDF
30. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas.
- Author
-
Nambu, Y, primary, Hughes, S J, additional, Rehemtulla, A, additional, Hamstra, D, additional, Orringer, M B, additional, and Beer, D G, additional
- Published
- 1998
- Full Text
- View/download PDF
31. ChemInform Abstract: Photochemistry of 1‐Alkoxy‐ and 1‐(Benzyloxy)‐9,10‐anthraquinones in Methanol: A δ‐Hydrogen Atom Abstraction Process That Exhibits a Captodative Effect.
- Author
-
BLANKESPOOR, R. L., primary, DE JONG, R. L., additional, DYKSTRA, R., additional, HAMSTRA, D. A., additional, ROZEMA, D. B., additional, VANMEURS, D. P., additional, and VINK, P., additional
- Published
- 1991
- Full Text
- View/download PDF
32. Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy.
- Author
-
Stegman, L D, Rehemtulla, A, Hamstra, D A, Rice, D J, Jonas, S J, Stout, K L, Chenevert, T L, and Ross, B D
- Subjects
GLIOMAS ,ADENOSINE deaminase ,GENE therapy ,MAGNETIC resonance imaging - Abstract
Detection of a therapeutic response early in the course of cancer treatment, before tumor growth delay or regression, is not currently possible in experimental models or clinical medicine. New interim measures of therapeutic response would be particularly useful in the development of cancer chemosensitization gene therapy by facilitating optimization of gene transfer protocols and prodrug dosing schedules. Diffusion MRI is a sensitive technique producing quantitative and noninvasive images of the apparent mobility of water within a tissue. We investigated the utility of diffusion MRI for detecting early changes associated with a refined cytosine deaminase (CD)/5-fluorocytosine (5FC) chemosensitization gene therapy paradigm in orthotopic 9L gliomas stably expressing the recently cloned S. cerevisiae CD gene. Mean tumor diffusion increased 31% within 8 days of initiating 5FC treatment, preceding tumor growth arrest and regression. Complete regression of the intracranial tumor was observed in four of five treated animals, and recurrent tumor in the remaining animal exhibited water diffusion behavior similar to primary, untreated tumors. These results demonstrate the efficacy of the yCD/5FC strategy for glioma and suggest that increased tumor water diffusion is an indicator of active therapeutic intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
33. The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer
- Author
-
Murgic Jure, Stenmark Matthew H, Halverson Schuyler, Blas Kevin, Feng Felix Y, and Hamstra Daniel A
- Subjects
Prostate cancer ,Biopsy ,prognostic factors ,Maximum involvement ,Tumor in Core ,Radiotherapy ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Purpose To evaluate the influence of the maximum involvement of biopsy core (MIBC) on outcome for prostate cancer patients treated with dose-escalated external beam radiotherapy (EBRT). Methods and materials The outcomes of 590 men with localized prostate cancer treated with EBRT (≥75 Gy) at a single institution were retrospectively analyzed. The influence of MIBC on freedom from biochemical failure (FFBF), freedom from metastasis (FFM), cause-specific survival (CSS), and overall survival (OS) was compared to other surrogates for biopsy tumor volume, including the percentage of positive biopsy cores (PPC) and the total percentage of cancer volume (PCV). Results MIBC correlated with PSA, T-stage, Gleason score, NCCN risk group, PPC, PCV, and treatment related factors. On univariate analysis, MIBC was prognostic for all endpoints except OS; with greatest impact in those with Gleason scores of 8–10. However, on multivariate analysis, MIBC was only prognostic for FFBF (hazard ratio [HR] 1.9, p = 0.008), but not for FFM (p = 0.19), CSS (p = 0.16), and OS (p = 0.99). Conclusions In patients undergoing dose-escalated EBRT, MIBC had the greatest influence in those with Gleason scores of 8–10 but provided no additional prognostic data as compared to PPC and PCV, which remain the preferable prognostic variables in this patient population.
- Published
- 2012
- Full Text
- View/download PDF
34. Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy
- Author
-
Vainshtein Jeffrey, Abu-Isa Eyad, Olson Karin B, Ray Michael E, Sandler Howard M, Normolle Dan, Litzenberg Dale W, Masi Kathryn, Pan Charlie, and Hamstra Daniel A
- Subjects
Urethral-sparing IMRT ,Focal therapies ,Low risk prostate cancer ,Urinary quality-of-life ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Low-risk prostate cancer (PCa) patients have excellent outcomes, with treatment modality often selected by perceived effects on quality of life. Acute urinary symptoms are common during external beam radiotherapy (EBRT), while chronic symptoms have been linked to urethral dose. Since most low-risk PCa occurs in the peripheral zone (PZ), we hypothesized that EBRT using urethral sparing intensity modulated radiation therapy (US-IMRT) could improve urinary health-related quality of life (HRQOL) while maintaining high rates of PCa control. Methods Patients with National Comprehensive Cancer Network (NCCN) defined low-risk PCa with no visible lesion within 5 mm of the prostatic urethra on MRI were randomized to US-IMRT or standard (S-) IMRT. Prescription dose was 75.6 Gy in 41 fractions to the PZ + 3–5 mm for US-IMRT and to the prostate + 3 mm for S-IMRT. For US-IMRT, mean proximal and distal urethral doses were limited to 65 Gy and 74 Gy, respectively. HRQOL was assessed using the Expanded Prostate Cancer Index (EPIC) Quality of Life questionnaire. The primary endpoint was change in urinary HRQOL at 3 months. Results From June 2004 to November 2006, 16 patients were randomized, after which a futility analysis concluded that continued accrual was unlikely to demonstrate a difference in the primary endpoint. Mean change in EPIC urinary HRQOL at 3 months was −0.5 ± 11.2 in the US-IMRT arm and +3.9 ± 15.3 in the S-IMRT arm (p = 0.52). Median PSA nadir was higher in the US-IMRT arm (1.46 vs. 0.78, p = 0.05). At 4.7 years median follow-up, three US-IMRT and no S-IMRT patients experienced PSA failure (p = 0.06; HR 8.8, 95% CI 0.9–86). Two out of 3 patients with PSA failure had biopsy-proven local failure, both located contralateral to the original site of disease. Conclusions Compared with S-IMRT, US-IMRT failed to improve urinary HRQOL and resulted in higher PSA nadir and inferior biochemical control. The high rate of PSA failure and contralateral local failures in US-IMRT patients, despite careful selection of MRI-screened low-risk patients, serve as a cautionary tale for focal PCa treatments.
- Published
- 2012
- Full Text
- View/download PDF
35. Testicular Dysfunction in Male Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review.
- Author
-
Baliga S, Patel S, Naqa IE, Li XA, Cohen LE, Howell RM, Hoppe BS, Constine LS, Palmer JD, Hamstra D, and Olch AJ
- Subjects
- Adolescent, Adult, Child, Humans, Male, Young Adult, Follicle Stimulating Hormone blood, Luteinizing Hormone blood, Luteinizing Hormone metabolism, Neoplasms radiotherapy, Organs at Risk radiation effects, Radiotherapy Dosage, Sperm Count, Testosterone blood, Testosterone metabolism, Cancer Survivors statistics & numerical data, Infertility, Male blood, Infertility, Male epidemiology, Infertility, Male etiology, Infertility, Male pathology, Oligospermia blood, Oligospermia epidemiology, Oligospermia etiology, Oligospermia pathology, Radiation Injuries blood, Radiation Injuries epidemiology, Radiation Injuries etiology, Radiation Injuries pathology, Testis metabolism, Testis pathology, Testis radiation effects
- Abstract
Purpose: The male reproductive task force of the Pediatric Normal Tissue Effects in the Clinic (PENTEC) initiative performed a comprehensive review that included a meta-analysis of publications reporting radiation dose-volume effects for risk of impaired fertility and hormonal function after radiation therapy for pediatric malignancies., Methods and Materials: The PENTEC task force conducted a comprehensive literature search to identify published data evaluating the effect of testicular radiation dose on reproductive complications in male childhood cancer survivors. Thirty-one studies were analyzed, of which 4 had testicular dose data to generate descriptive scatter plots. Two cohorts were identified. Cohort 1 consisted of pediatric and young adult patients with cancer who received scatter radiation therapy to the testes. Cohort 2 consisted of pediatric and young adult patients with cancer who received direct testicular radiation therapy as part of their cancer therapy. Descriptive scatter plots were used to delineate the relationship between the effect of mean testicular dose on sperm count reduction, testosterone, follicle stimulating hormone (FSH), and luteinizing hormone (LH) levels., Results: Descriptive scatter plots demonstrated a 44% to 80% risk of oligospermia when the mean testicular dose was <1 Gy, but this was recovered by >12 months in 75% to 100% of patients. At doses >1 Gy, the rate of oligospermia increased to >90% at 12 months. Testosterone levels were generally not affected when the mean testicular dose was <0.2 Gy but were abnormal in up to 25% of patients receiving between 0.2 and 12 Gy. Doses between 12 and 19 Gy may be associated with abnormal testosterone in 40% of patients, whereas doses >20 Gy to the testes were associated with a steep increase in abnormal testosterone in at least 68% of patients. FSH levels were unaffected by a mean testicular dose <0.2 Gy, whereas at doses >0.5 Gy, the risk was between 40% and 100%. LH levels were affected at doses >0.5 Gy in 33% to 75% of patients between 10 and 24 months after radiation. Although dose modeling could not be performed in cohort 2, the risk of reproductive toxicities was escalated with doses >10 Gy., Conclusions: This PENTEC comprehensive review demonstrates important relationships between scatter or direct radiation dose on male reproductive endpoints including semen analysis and levels of FSH, LH, and testosterone., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
36. Hormonal status effects on the electrophysiological correlates of performance monitoring in women.
- Author
-
Jansen M, Van der Does AJW, De Rover M, De Bruijn ERA, and Hamstra DA
- Subjects
- Humans, Female, Electroencephalography, Affect physiology, Anxiety Disorders, Progesterone pharmacology, Estradiol pharmacology
- Abstract
Fluctuations in ovarian hormones are thought to play a role in the increased prevalence of mood and anxiety disorders in women. Error-related negativity (ERN) and error positivity (Pe) are two putative electrophysiological biomarkers for these internalizing disorders. We investigated whether female hormonal status, specifically menstrual cycle phase and oral contraceptive (OC) use, impact ERN and Pe. Additionally, we examined whether the relationship between the ERN and negative affect (NA) was moderated by hormonal status and tested whether the ERN mediated the relation between ovarian hormones and NA. Participants were healthy, pre-menopausal women who were naturally cycling (NC) or using OCs. Using a counterbalanced within-subject design, all participants performed a speeded-choice reaction-time task twice while undergoing electroencephalography measurements. NC women (N = 42) performed this task during the early follicular and midluteal phase (when estrogen and progesterone are both low and both high, respectively), while OC users (N = 42) performed the task during active OC use and during their pill-free week. Estradiol and progesterone levels were assessed in saliva. Comparing the two cycle phases within NC women revealed no differences in the (Δ)ERN, (Δ)Pe or NA. We did observe a negative relation between phase-related changes in the ΔERN and changes in NA. Mediation analysis additionally showed that phase-related changes in estradiol were indirectly and negatively related to NA through a reduction of ΔERN amplitudes. When comparing active OC users with NC women, we observed increased ΔPe- but not (Δ)ERN amplitudes in the former group. No evidence was found for moderating effects of menstrual cycle phase or OC use on the relation between the ERN and NA. These findings suggest that hormonal status may impact the neural correlates of performance monitoring and error sensitivity, and that this could be a potential mechanism through which ovarian hormones influence mood., Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest to declare., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
37. Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiation Therapy.
- Author
-
Quinn TJ, Chapman D, Parzen J, Wahl DR, McNamara A, Dess R, Chan J, Feng F, Jackson WC, and Hamstra D
- Subjects
- Male, Humans, Neoplasm Grading, Prognosis, Prostate-Specific Antigen, Prostate pathology, Prostatic Neoplasms pathology
- Abstract
Purpose: Prognostic factors for prostate cancer include tumor, node, metastases stage, pretreatment prostate-specific antigen, and pathology (via Gleason score [GS] or grade group). Of these, GS yields the largest effect on prostate cancer specific mortality. It was previously determined that those with cores with a mix of higher and lower GS at biopsy (which was termed a "ComboGS") had decreased risk for prostate cancer specific mortality after either surgical or radiation treatment. We validate the effect of ComboGS in an independent cohort of patients with prostate cancer treated with definitive dose-escalated radiation therapy (DE-RT) at 2 institutions., Methods and Materials: DE-RT was administered to 2539 men, of which 687 men had a ComboGS. To further ascertain the ComboGS effect we employed the modified Cancer of the Prostate Risk Assessment (mCAPRA) score. Rates of biochemical event-free survival and distant metastasis-free survival were compared across CAPRA scores, with and without modification, and the prognostic value of the CAPRA scores was compared using Harrel's concordance index., Results: On univariate analysis in Gleason 7 to 10 patients the presence of ComboGS improved 10-year biochemical event-free survival from 76.6% to 82.4% (hazard ratio [HR], 0.75; confidence interval [CI], 0.59-0.96; P = .021), 10-year distant metastasis-free survival from 89.3% to 93.2% (HR, 0.57; CI, 0.39-0.85; P = .005), 10-year prostate cancer specific survival from 93.9% to 97.4% (HR, 0.39; CI, 0.21-0.7; P = .001), and 10-year overall survival from 65.7% to 75.6% (HR, 0.69; CI, 0.57-0.83; P < .001). Multivariable analysis also supported that ComboGS is protective for biochemical failure (HR, 0.64; CI, 0.50-0.83; P < .001), distant metastasis (HR, 0.42; CI, 0.28-0.63; P < .001), death from prostate cancer (HR, 0.32; CI, 0.17-0.58; P < .001), and overall mortality (HR, 0.65; CI, 0.54-0.79; P < .001). Additionally, adjusting the mCAPRA score for ComboGS decreased the risk of biochemical failure by nearly 30% (HR, 0.70; 95% CI, 0.55-0.88; P = .003) and by 50% (HR, 0.54; 95% CI, 0.37-0.80; P = .002) for distant metastasis., Conclusions: ComboGS is a useful and readily available independent prognostic factor for all clinical endpoints evaluated. Moreover, the ComboGS can be used in conjunction with the extensively validated CAPRA scoring to better risk stratify patients being treated with definitive DE-RT for GS 7 to 10 disease., (Copyright © 2022 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
38. Two Specialists, Two Recommendations: Discordance Between Urologists' & Radiation Oncologists' Prostate Cancer Treatment Recommendations.
- Author
-
Delaney RK, Sisco-Taylor BL, Wang X, Scherr K, Ubel PA, Haaland B, Kahn VC, Hamstra D, Wei JT, Madanay F, Davis JK, Greeno TU, and Fagerlin A
- Subjects
- Male, Humans, Middle Aged, Urologists, Radiation Oncologists, Practice Patterns, Physicians', Urology, Radiation Oncology, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms surgery
- Abstract
Objective: To examine the treatment recommendation patterns among urologists and radiation oncologists, the level of concordance or discordance between physician recommendations, and the association between physician recommendations and the treatment that patients received., Method: The study was a secondary analysis of data from a randomized clinical trial conducted November 2010 to April 2014 (NCT02053389). Eligible participants were patients from the trial who saw both specialists. The primary outcome was physician recommendations that were scored using an adapted version of the validated PhyReCS coding system. Secondary outcomes included concordance between physician recommendations and the treatment patients received., Results: Participants were 108 patients (Mean age 61.9 years; range 43-82; 87% non-Hispanic White). Urologists were more likely to recommend surgery (79% of recommendations) and radiation oncologists were more likely to recommend radiation (68% of recommendations). Recommendations from the urologists and radiation oncologists were concordant for only 33 patients (30.6%). Most patients received a treatment that both physicians recommended (59%); however, 35% received a treatment that only one of their physicians recommended. When discordant, urologists more often recommended surgery and radiation oncologists recommended radiation and surgery as equally appropriate options., Conclusion: Urologists and radiation oncologists are more likely to differ than agree in their treatment recommendations for the same patients with clinically localized prostate cancer and more likely to favor treatment aligned with their specialty. Additional studies are needed to better understand how patients make decisions after meeting with two different specialists to inform the development of best practices within oncology clinics., (Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
39. Oral D-methionine protects against cisplatin-induced hearing loss in humans: phase 2 randomized clinical trial in India.
- Author
-
Campbell KC, Rehemtulla A, Sunkara P, Hamstra D, Buhnerkempe M, and Ross B
- Subjects
- Adult, Auditory Threshold, Cisplatin toxicity, Humans, India, Ototoxicity prevention & control, Hearing Loss chemically induced, Hearing Loss diagnosis, Hearing Loss prevention & control, Methionine therapeutic use
- Abstract
Objective: This exploratory Phase 2 clinical trial is the first determining safety and efficacy of oral D-methionine (D-met) in reducing cisplatin-induced ototoxicity. Design: Randomised parallel double-blind placebo-controlled exploratory Phase 2 study. Study samples: Fifty adult cancer patients received oral D-met or placebo before each cisplatin dose. Physical examination, blood collection and audiometry occurred at baseline and subsequent visits plus post-treatment audiometry. After attrition, final analysis included 27 patients. Results: Significant treatment group by ear and time (baseline vs. post-treatment) interactions occurred at 10 kHz and 11.2 kHz. Placebo and D-met groups differed in threshold shift for left ear at 11.2 kHz (mean difference = 22.97 dB [9.59, 36.35]). Averaging across ears, placebo group showed significant threshold shifts from baseline to post-treatment at 10 kHz (mean shift= -13.65 dB [-21.32,-5.98]), 11.2 kHz (-16.15 dB [-25.19,-7.12]), and 12.5 kHz (-11.46 dB [-19.18,-3.74]) but not 8 kHz (-8.65 dB [-17.86, 0.55]). The D-met group showed no significant threshold shifts (8 kHz: -1.25 dB [-7.75, 5.25]; 10 kHz:-3.93 dB [-8.89, 1.03]; 11.2 kHz:-4.82 dB [-11.21, 1.57]; 12.5 kHz:-3.68 dB [-11.57, 4.21]). Side effects did not significantly differ between groups. Conclusion: Oral D-met reduces cisplatin-induced ototoxicity in humans.
- Published
- 2022
- Full Text
- View/download PDF
40. Preparing Patients with Early Stage Prostate Cancer to Participate in Clinical Appointments Using a Shared Decision Making Training Video.
- Author
-
Scherr K, Delaney RK, Ubel P, Kahn VC, Hamstra D, Wei JT, and Fagerlin A
- Subjects
- Decision Making, Decision Making, Shared, Humans, Male, Patient Participation, Physicians, Prostatic Neoplasms therapy
- Abstract
Background: Rates of shared decision making (SDM) are relatively low in early stage prostate cancer decisions, as patients' values are not well integrated into a preference-sensitive treatment decision. The study objectives were to develop a SDM training video, measure usability and satisfaction, and determine the effect of the intervention on preparing patients to participate in clinical appointments., Methods: A randomized controlled trial was conducted to compare a plain-language decision aid (DA) to the DA plus a patient SDM training video. Patients with early stage prostate cancer completed survey measures at baseline and after reviewing the intervention materials. Survey items assessed patients' knowledge, beliefs related to SDM, and perceived readiness/intention to participate in their upcoming clinical appointment., Results: Of those randomized to the DA + SDM video group, most participants (91%) watched the video and 93% would recommend the video to others. Participants in the DA + SDM video group, compared to the DA-only group, reported an increased desire to participate in the decision (mean = 3.65 v. 3.39, P < 0.001), less decision urgency (mean = 2.82 v. 3.39, P < 0.001), and improved self-efficacy for communicating with physicians (mean = 4.69 v. 4.50, P = 0.05). These participants also reported increased intentions to seek a referral from a radiation oncologist (73% v. 51%, P = 0.004), to take notes (mean = 3.23 v. 2.86, P = 0.004), and to record their upcoming appointments (mean = 1.79 v. 1.43, P = 0.008)., Conclusions: A novel SDM training video was accepted by patients and changed several measures associated with SDM. This may be a scalable, cost-effective way to prepare patients with early stage prostate cancer to participate in their clinical appointments.[Box: see text].
- Published
- 2022
- Full Text
- View/download PDF
41. Ethical Allocation of Proton Therapy and the Insurance Review Process.
- Author
-
Grzywacz V, Quinn TJ, Wilson T, Reitemeier P, Navin M, Hamstra D, Anderson J, Chinnaiyan P, Stevens C, and Kabolizadeh P
- Subjects
- Aged, Humans, Medicare, Odds Ratio, United States, Proton Therapy
- Abstract
Purpose: The purpose of this study was to delineate a scoring system to maximize the ethical allocation of proton beam therapy (PBT) and determine what factors are associated with receipt of PBT, including the role of specific insurance providers., Methods and Materials: Our scoring system was developed in collaboration with a multidisciplinary panel of experts. Patients submitted for PBT consideration were assigned a score by committee at a weekly peer-reviewed session at a time when our center was operating at capacity. Univariate analysis and multivariable analysis of initial and final insurance response were performed., Results: One hundred ninety-seven patients were prospectively reviewed. Ninety-three percent of patients with Medicaid coverage, 88% of patients with Medicare, and 78% of patients with private insurance were ultimately approved for PBT. Median time to final insurance response was 12 days (interquartile range, 9-18 days) for patients who were ultimately denied PBT coverage. Having primary provider C (odds ratio [OR], 14; 95% confidence interval [CI], 1.20-1.96; P = .033) or third party providers A (OR, 4.22; 95% CI, 1.71-10.9; P = .002) or B (OR, 5.28; 95% CI, 1.56-17.2; P = .006) was significantly associated with final insurance denial for PBT on univariate analysis. Total score (OR, 0.79; 95% CI, 0.67-0.90; P = .002) and having coverage through third party provider A (OR, 24.2; 95% CI, 9.51-68.9; P < .001) were associated with final insurance response on multivariable analysis., Conclusions: Our scoring system was significantly associated with receipt of proton beam therapy. Certain insurance providers are less likely to approve PBT for patients, all else being equal. Such a scoring system could be implemented effectively at other PBT facilities, and additional work is needed in ensuring patients with the most to gain from PBT will be approved by their insurance providers., (Copyright © 2021 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
42. VA-Radiation Oncology Quality Surveillance Program.
- Author
-
Hagan M, Kapoor R, Michalski J, Sandler H, Movsas B, Chetty I, Lally B, Rengan R, Robinson C, Rimner A, Simone C, Timmerman R, Zelefsky M, DeMarco J, Hamstra D, Lawton C, Potters L, Valicenti R, Mutic S, Bosch W, Abraham C, Caruthers D, Brame R, Palta JR, Sleeman W, and Nalluri J
- Subjects
- Carcinoma, Non-Small-Cell Lung radiotherapy, Evidence-Based Medicine standards, Humans, Lung Neoplasms radiotherapy, Male, Peer Review, Program Evaluation standards, Prostatic Neoplasms radiotherapy, Quality Assurance, Health Care methods, Quality Improvement standards, Quality Indicators, Health Care standards, Small Cell Lung Carcinoma radiotherapy, Societies, Medical standards, United States, Veterans, Cancer Care Facilities standards, Hospitals, Veterans standards, Program Development, Quality Assurance, Health Care standards, Radiation Oncology standards
- Abstract
Purpose: We sought to develop a quality surveillance program for approximately 15,000 US veterans treated at the 40 radiation oncology facilities at the Veterans Affairs (VA) hospitals each year., Methods and Materials: State-of-the-art technologies were used with the goal to improve clinical outcomes while providing the best possible care to veterans. To measure quality of care and service rendered to veterans, the Veterans Health Administration established the VA Radiation Oncology Quality Surveillance program. The program carries forward the American College of Radiology Quality Research in Radiation Oncology project methodology of assessing the wide variation in practice pattern and quality of care in radiation therapy by developing clinical quality measures (QM) used as quality indices. These QM data provide feedback to physicians by identifying areas for improvement in the process of care and identifying the adoption of evidence-based recommendations for radiation therapy., Results: Disease-site expert panels organized by the American Society for Radiation Oncology (ASTRO) defined quality measures and established scoring criteria for prostate cancer (intermediate and high risk), non-small cell lung cancer (IIIA/B stage), and small cell lung cancer (limited stage) case presentations. Data elements for 1567 patients from the 40 VA radiation oncology practices were abstracted from the electronic medical records and treatment management and planning systems. Overall, the 1567 assessed cases passed 82.4% of all QM. Pass rates for QM for the 773 lung and 794 prostate cases were 78.0% and 87.2%, respectively. Marked variations, however, were noted in the pass rates for QM when tumor site, clinical pathway, or performing centers were separately examined., Conclusions: The peer-review protected VA-Radiation Oncology Surveillance program based on clinical quality measures allows providers to compare their clinical practice to peers and to make meaningful adjustments in their personal patterns of care unobtrusively., (Copyright © 2019. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
43. Hypofractionation in Prostate Cancer Using Proton Beam.
- Author
-
Quinn TJ and Hamstra D
- Subjects
- Humans, Male, Prospective Studies, Protons, Radiation Dose Hypofractionation, Prostatic Neoplasms, Proton Therapy
- Published
- 2019
- Full Text
- View/download PDF
44. Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization.
- Author
-
Foster B, Jackson W, Foster C, Dess R, Abu-Isa E, McLaughlin PW, Merrick G, Hearn J, Spratt D, Liauw S, and Hamstra D
- Subjects
- Aged, Follow-Up Studies, Humans, Male, Prognosis, Prostatic Neoplasms blood, Prostatic Neoplasms radiotherapy, Radiotherapy Dosage, Retrospective Studies, Risk Factors, Survival Rate, Brachytherapy mortality, Brachytherapy standards, Prostate-Specific Antigen blood, Prostatic Neoplasms pathology
- Abstract
Objectives: We applied an established prognostic model to high-risk prostate cancer (HRPC) patients treated with radiotherapy (RT) and evaluated the influence of clinical and treatment variables on treatment outcomes., Methods: In total, 1075 HRPC patients undergoing definitive radiotherapy (RT) between 1995 and 2010 were retrospectively reviewed. Median follow-up was 62.3 months. Patients received either dose-escalated external beam radiotherapy (n=628, EBRT) or combined-modality radiotherapy (n=447, pelvic RT and low-dose rate brachytherapy boost, CMRT). 82.9% received androgen-deprivation therapy (ADT). A prognostic model stratified patients into predefined groups (good, intermediate, and poor). Kaplan-Meier methods and Cox proportional hazards regressions assessed biochemical failure (BF), distant metastasis (DM), prostate cancer-specific mortality (PCSM) and overall mortality (OM). C-indices analyzed predictive value., Results: The model was prognostic; C-indices for BF, DM, PCSM and OM were: 0.62, 0.64, 0.61, and 0.57. On multivariate analysis, CMRT and longer ADT (≥24 mo) were associated with improved BF, DM, and PCSM. Gleason score (GS) 9-10 was the strongest predictor of PCSM. C-indices for BF, DM, PCSM, and OM using a 4-compartment model incorporating GS 9-10 were: 0.62, 0.65, 0.68, and 0.56. In poor-prognosis patients (GS 8-10+additional risk factors), CMRT+LTADT (>12 mo) had 10-year PCSM (3.7%±3.6%), comparing favorably to 25.8%±9.2% with EBRT+LTADT., Conclusions: The model applies to high-risk RT patients; GS 9-10 remains a powerful predictor of PCSM. Comparing similar prognosis patients, CMRT is associated with improved disease-specific outcomes relative to EBRT. In poor-prognosis patients, CMRT+LTADT yields superior 10-year PCSM, potentially improving RT treatment personalization for those with HRPC.
- Published
- 2019
- Full Text
- View/download PDF
45. Quality of life is not compromised with intensification of androgen therapy in recurrent prostate cancer.
- Author
-
Seymour Z and Hamstra D
- Subjects
- Androgen Antagonists, Humans, Male, Neoplasm Recurrence, Local, Quality of Life, Thiohydantoins, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
- Published
- 2018
- Full Text
- View/download PDF
46. Knowledge-based treatment planning and its potential role in the transition between treatment planning systems.
- Author
-
Masi K, Archer P, Jackson W, Sun Y, Schipper M, Hamstra D, and Matuszak M
- Subjects
- Humans, Male, Prostatic Neoplasms radiotherapy, Radiotherapy Planning, Computer-Assisted
- Abstract
Commissioning a new treatment planning system (TPS) involves many time-consuming tasks. We investigated the role that knowledge-based planning (KBP) can play in aiding a clinic's transition to a new TPS. Sixty clinically treated prostate/prostate bed intensity-modulated radiation therapy (IMRT) plans were exported from an in-house TPS and were used to create a KBP model in a newly implemented commercial application. To determine the benefit that KBP may have in a TPS transition, the model was tested on 2 groups of patients. Group 1 consisted of the first 10 prostate/prostate bed patients treated in the commercial TPS after the transition from the in-house TPS. Group 2 consisted of 10 patients planned in the commercial TPS after 8 months of clinical use. The KBP-generated plan was compared with the clinically used plan in terms of plan quality (ability to meet planning objectives and overall dose metrics) and planning efficiency (time required to generate clinically acceptable plans). The KBP-generated plans provided a significantly improved target coverage (p = 0.01) compared with the clinically used plans for Group 1, but yielded plans of comparable target coverage to the clinically used plans for Group 2. For the organs at risk, the KBP-generated plans produced lower doses, on average, for every normal-tissue objective except for the maximum dose to 0.1 cc of rectum. The time needed for the KBP-generated plans ranged from 6 to 15 minutes compared to 30 to 150 and 15 to 60 minutes for manual planning in Groups 1 and 2, respectively. KBP is a promising tool to aid in the transition to a new TPS. Our study indicates that high-quality treatment plans could have been generated in the newly implemented TPS more efficiently compared with not using KBP. Even after 8 months of the clinical use, KBP still showed an increase in plan quality and planning efficiency compared with manual planning., (Copyright © 2017 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
47. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
- Author
-
Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, Lau H, Duclos M, Parliament M, Morton G, Hamstra D, Seider M, Lock MI, Patel M, Gay H, Vigneault E, Winter K, and Sandler H
- Subjects
- Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Radiation, Follow-Up Studies, Gastrointestinal Diseases etiology, Humans, Kaplan-Meier Estimate, Male, Male Urogenital Diseases etiology, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Radiation Injuries epidemiology, Radiation Injuries etiology, Radiotherapy, Intensity-Modulated, Salvage Therapy statistics & numerical data, Treatment Outcome, Prostatic Neoplasms radiotherapy, Radiotherapy Dosage, Radiotherapy, Conformal
- Abstract
Importance: Optimizing radiation therapy techniques for localized prostate cancer can affect patient outcomes. Dose escalation improves biochemical control, but no prior trials were powered to detect overall survival (OS) differences., Objective: To determine whether radiation dose escalation to 79.2 Gy compared with 70.2 Gy would improve OS and other outcomes in prostate cancer., Design, Setting, and Participants: The NRG Oncology/RTOG 0126 randomized clinical trial randomized 1532 patients from 104 North American Radiation Therapy Oncology Group institutions March 2002 through August 2008. Men with stage cT1b to T2b, Gleason score 2 to 6, and prostate-specific antigen (PSA) level of 10 or greater and less than 20 or Gleason score of 7 and PSA less than 15 received 3-dimensional conformal radiation therapy or intensity-modulated radiation therapy to 79.2 Gy in 44 fractions or 70.2 Gy in 39 fractions., Main Outcomes and Measures: Time to OS measured from randomization to death due to any cause. American Society for Therapeutic Radiology and Oncology (ASTRO)/Phoenix definitions were used for biochemical failure. Acute (≤90 days of treatment start) and late radiation therapy toxic effects (>90 days) were graded using the National Cancer Institute Common Toxicity Criteria, version 2.0, and the RTOG/European Organisation for the Research and Treatment of Cancer Late Radiation Morbidity Scoring Scheme, respectively., Results: With a median follow-up of 8.4 (range, 0.02-13.0) years in 1499 patients (median [range] age, 71 [33-87] years; 70% had PSA <10 ng/mL, 84% Gleason score of 7, 57% T1 disease), there was no difference in OS between the 751 men in the 79.2-Gy arm and the 748 men in the 70.2-Gy arm. The 8-year rates of OS were 76% with 79.2 Gy and 75% with 70.2 Gy (hazard ratio [HR], 1.00; 95% CI, 0.83-1.20; P = .98). The 8-year cumulative rates of distant metastases were 4% for the 79.2-Gy arm and 6% for the 70.2-Gy arm (HR, 0.65; 95% CI, 0.42-1.01; P = .05). The ASTRO and Phoenix biochemical failure rates at 5 and 8 years were 31% and 20% with 79.2 Gy and 47% and 35% with 70.2 Gy, respectively (both P < .001; ASTRO: HR, 0.59; 95% CI, 0.50-0.70; Phoenix: HR, 0.54; 95% CI, 0.44-0.65). The high-dose arm had a lower rate of salvage therapy use. The 5-year rates of late grade 2 or greater gastrointestinal and/or genitourinary toxic effects were 21% and 12% with 79.2 Gy and 15% and 7% with 70.2 Gy (P = .006 [HR, 1.39; 95% CI, 1.10-1.77] and P = .003 [HR, 1.59; 95% CI, 1.17-2.16], respectively)., Conclusions and Relevance: Despite improvements in biochemical failure and distant metastases, dose escalation did not improve OS. High doses caused more late toxic effects but lower rates of salvage therapy., Trial Registration: clinicaltrials.gov Identifier: NCT00033631.
- Published
- 2018
- Full Text
- View/download PDF
48. Point: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Quality of Life is Better After Modern Radiotherapy Compared With Surgery.
- Author
-
Yu JB and Hamstra D
- Subjects
- Humans, Male, Prostatic Neoplasms psychology, Prostatectomy, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms surgery, Quality of Life
- Published
- 2017
49. Defining a standard set of patient-centered outcomes for men with localized prostate cancer.
- Author
-
Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A, Blute M, Catto J, Chen RC, D'Amico AV, Feick G, Fitzpatrick JM, Frank SJ, Froehner M, Frydenberg M, Glaser A, Graefen M, Hamstra D, Kibel A, Mendenhall N, Moretti K, Ramon J, Roos I, Sandler H, Sullivan FJ, Swanson D, Tewari A, Vickers A, Wiegel T, and Huland H
- Subjects
- Consensus, Delphi Technique, Disease Progression, Disease-Free Survival, Drug-Related Side Effects and Adverse Reactions etiology, Humans, Male, Postoperative Complications etiology, Practice Patterns, Physicians' standards, Predictive Value of Tests, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Quality Improvement standards, Quality of Life, Radiation Injuries etiology, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Health Status, Health Status Indicators, Medical Oncology standards, Patient-Centered Care standards, Process Assessment, Health Care standards, Prostatic Neoplasms therapy, Quality Indicators, Health Care standards
- Abstract
Background: Value-based health care has been proposed as a unifying force to drive improved outcomes and cost containment., Objective: To develop a standard set of multidimensional patient-centered health outcomes for tracking, comparing, and improving localized prostate cancer (PCa) treatment value., Design, Setting, and Participants: We convened an international working group of patients, registry experts, urologists, and radiation oncologists to review existing data and practices., Outcome Measurements and Statistical Analysis: The group defined a recommended standard set representing who should be tracked, what should be measured and at what time points, and what data are necessary to make meaningful comparisons. Using a modified Delphi method over a series of teleconferences, the group reached consensus for the Standard Set., Results and Limitations: We recommend that the Standard Set apply to men with newly diagnosed localized PCa treated with active surveillance, surgery, radiation, or other methods. The Standard Set includes acute toxicities occurring within 6 mo of treatment as well as patient-reported outcomes tracked regularly out to 10 yr. Patient-reported domains of urinary incontinence and irritation, bowel symptoms, sexual symptoms, and hormonal symptoms are included, and the recommended measurement tool is the Expanded Prostate Cancer Index Composite Short Form. Disease control outcomes include overall, cause-specific, metastasis-free, and biochemical relapse-free survival. Baseline clinical, pathologic, and comorbidity information is included to improve the interpretability of comparisons., Conclusions: We have defined a simple, easily implemented set of outcomes that we believe should be measured in all men with localized PCa as a crucial first step in improving the value of care., Patient Summary: Measuring, reporting, and comparing identical outcomes across treatments and treatment centers will provide patients and providers with information to make informed treatment decisions. We defined a set of outcomes that we recommend being tracked for every man being treated for localized prostate cancer., (Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
50. Mineralocorticoid receptor haplotype, oral contraceptives and emotional information processing.
- Author
-
Hamstra DA, de Kloet ER, van Hemert AM, de Rijk RH, and Van der Does AJ
- Subjects
- Adult, Cross-Sectional Studies, Decision Making physiology, Emotions physiology, Facial Expression, Female, Haplotypes, Humans, Mental Recall physiology, Recognition, Psychology physiology, Young Adult, Contraceptives, Oral, Hormonal adverse effects, Decision Making drug effects, Emotions drug effects, Mental Recall drug effects, Receptors, Mineralocorticoid genetics, Recognition, Psychology drug effects
- Abstract
Background: Oral contraceptives (OCs) affect mood in some women and may have more subtle effects on emotional information processing in many more users. Female carriers of mineralocorticoid receptor (MR) haplotype 2 have been shown to be more optimistic and less vulnerable to depression., Aim: To investigate the effects of oral contraceptives on emotional information processing and a possible moderating effect of MR haplotype., Methods: Cross-sectional study in 85 healthy premenopausal women of West-European descent., Results: We found significant main effects of oral contraceptives on facial expression recognition, emotional memory and decision-making. Furthermore, carriers of MR haplotype 1 or 3 were sensitive to the impact of OCs on the recognition of sad and fearful faces and on emotional memory, whereas MR haplotype 2 carriers were not., Limitations: Different compounds of OCs were included. No hormonal measures were taken. Most naturally cycling participants were assessed in the luteal phase of their menstrual cycle., Conclusions: Carriers of MR haplotype 2 may be less sensitive to depressogenic side-effects of OCs., (Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.